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Abstract
Several recent studies have assessed the use of biomarkers of Acute Kidney Injury (AKI),
but the information among patients with stone disease and those with obstructive
uropathy is limited. For this reason, we conducted a prospective cohort study to
determine the urinary levels of KIM-1, Total and Monomeric NGAL in patients with
hydronephrosis secondary to renal stone disease, congenital ureteropelvic junction
obstruction or ureteral stricture, and in a group of healthy controls in our health care
center. Urinary biomarker concentrations were evaluated before and after surgical
treatment. Patients with hydronephrosis showed significantly higher baseline levels of
KIM-1 compared to those patients without hydronephrosis. KIM-1 was the only urinary
biomarker significantly affected by the presence of hydronephrosis. Total and Monomeric
NGAL correlated with the presence of leukocyturia. Our results show that KIM-1 is a
promising biomarker of subclinical AKI associated with hydronephrosis in urological
patients.

Keywords
Acute kidney injury (AKI), Hydronephrosis, Urinary biomarkers, Stone disease, Urinary
tract obstruction, Ureteropelvic junction obstruction (UPJO), KIM-1, Total NGAL,
Monomeric NGAL
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Background

Partial or complete obstruction of the urinary tract is a common and challenging
urological condition that may occur in patients of any age. Urinary tract obstruction can
be classified as congenital or acquired, depending on the cause; acute or chronic,
according to the time of evolution, and benign or malignant. Alternatively, it can be
catalogued as upper or lower urinary tract obstruction, depending on the location as well
as unilateral or bilateral. Obstruction of the urinary tract may be silent, can cause mild
and longstanding symptoms or it may be the reason for an emergency treatment, such as
patients with renal colic or acute urinary retention. The main concerns of urinary
obstruction are pain, renal function loss, and the increased possibility of an infectious
process. Several factors play an important role in the pathophysiology of urinary tract
obstruction and these will be reviewed in more detail in the next sections.
Until recently, serum creatinine was considered an accurate marker to assess global renal
function. Many diagnostic and therapeutic decisions have been based on the levels of this
compound in blood that does not always precisely reflect the current status of kidney
function. Lately, several studies have been dedicated to the scrutiny of newly discovered
kidney proteins released through blood and urine that may be used as acute kidney injury
(AKI) markers (Nickolas, 2008; Zappitelli, 2007). Numerous markers have been
described in different patient populations and some have been proposed as potential
substitutes for creatinine as an objective measure of AKI.
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The most commonly investigated biomarkers are Kidney Injury Molecule-1 (KIM-1),
Neutrophil Gelatinase-associated Lipocalin (NGAL), cystatin C, B2-microglobulin,
interleukin-18, osteopontin and liver-type fatty acid-binding protein (L-FABP) (Koyner,
2010; Wasilewska, 2011). Unfortunately, few studies have addressed the diagnostic value
of these new markers in patients with urological comorbidities, or they lack of a
longitudinal follow-up to evaluate their real significance over time. For this reason, and in
order to provide a thoughtful understanding of the impact of these urinary AKI markers,
we designed and conducted this prospective cohort study in urological patients.
Throughout this chapter, we will explore the pathophysiology of unilateral and bilateral
urinary tract obstruction and how it affects the markers used to assess the function of the
kidney. Special attention will be paid to AKI, with emphasis on postrenal causes,
particularly to ureteric obstruction due to stricture or stone disease. Information about the
most commonly used urinary markers will be presented. A detailed description of
hydronephrosis and the grading scales are also included. Finally, the hypotheses of our
research project will be discussed and the possible clinical implications will be
underlined.

1.1 Defining urinary tract obstruction
Urinary tract obstruction (UTO) is the term used to define the blockage to the flow of
urine that causes elevated pressures within the collecting system of the urinary tract and
affects the normal function of the renal unit. It is usually a mechanical problem that can
cause renal dysfunction and occur at any level of the urinary tract, from the renal calyces
(i.e. infundibular stenosis) to the urethral meatus (i.e. urethral stenosis). The impact of the
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obstruction in patients´ health status is related to the location of the obstruction, the time
of onset, the baseline renal function and the presence of risk factors for electrolyte
imbalances or septic processes. It is useful to classify UTO according to the etiology,
location, bilateralism and time of onset, because this information will help to determine
the diagnosis and proper management. Figure 1 shows different ways of classifying
UTO, and Table 1 lists common examples associated with each type.

Figure 1: Classification of urinary tract obstruction according to the location and
level, etiology and time of onset (Campbell-Walsh, 2012; Loo, 1988).
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Table 1. Most common causes of urinary tract obstruction categorized by type.
(Adapted from Campbell-Walsh, 2012).

UTO is characterized by the presence of hydronephrosis on imaging studies and most
commonly detected by either renal ultrasound or abdominal Computerized Tomography
imaging (CT scan). According to these studies, the presence of unilateral or bilateral
obstruction may also give important clues about the cause. Hydronephrosis is not always
associated with mechanical obstruction, instead, it can be related to a functional disorder
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which leads to an impairment in urine flow, such as a hypocontractile bladder,
vesicoureteral reflux or a non-peristaltic ureter during a pyelonephritis episode. These
unique conditions where hydronephrosis is not related to obstruction were not included in
our study.

1.2 Functional changes associated with urinary tract
obstruction
Renal obstruction is associated with a myriad of hemodynamic and humoral responses
that lastly lead to a reduction in the Glomerular Filtration rate (GFR) of the renal unit.
GFR is a dynamic process determined by 3 different intimately related elements:
1. Glomerular ultrafiltration coefficient, which is the surface area of the glomerular
membrane
2. Glomerular capillary pressure influenced by afferent and efferent resistances in
glomerular vasculature.
3. Tubular regulation
UTO directly affects tubular regulation and the pathophysiology is different between
unilateral and bilateral obstruction; the ultrafiltration coefficient and the capillary
pressures may be affected in late phases of obstruction. Our knowledge comes from
animal experiments where an increased hydrostatic pressure in the tubular system
activates the cascade of events leading to renal fibrosis, although the complete kidney
response to these dynamic changes is not fully understood (Vaughan, 2004). Specific and
detailed description of the molecular biology of the kidney physiology is beyond the
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scope of this research, and we will focus on the hemodynamic and humoral changes
associated with urinary obstruction.

1.2.1 Pathophysiology of unilateral ureteral obstruction
The first study to evaluate kidney injury after complete unilateral ureteral occlusion was
carried out in the late 1960s, with a canine model measuring vascular and ureteral
pressures (Gillenwater, 1970). In fact, this was the foundation for further research in
renin-angiotensine-aldosterone system (RAAS), thromboxane A2 (TA2), and other
prostaglandins. Renal blood flow and ureteral pressures associated with unilateral
obstruction have a relationship that is described as a “triphasic response”, that proceeds
as follows: Phase 1) an increase in both the renal blood flow (RBF) and ureteral pressure
(UP) is followed by phase 2) with a drop in blood flow and elevated UP, and finally
phase 3) a decrease in both flow and pressure.
This response was depicted after an 18-hour evaluation of unilateral ureteral obstruction
(UUO) in a canine model and it is currently valid to understand the pathophysiology of
complete UUO. Figure 2 shows the 3 phases initially described by Moody et al in 1975
and several new findings have augmented our knowledge about this topic, where
biochemical and hormonal interactions modulate renal responses.
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Figure 2: Triphasic relationship between the renal blood flow and ureteral
pressure after unilateral obstruction (From Loo, 1988; with permission from
Springer).

During the first two hours, the increased UP causes an immediate response regulated by
Prostaglandin E2 (PGE2) and Nitrous Oxide to increase the RBF and maintain the normal
GFR (Salvamini, 1994; Vaughan, 2004). This increment in UP depends on the GFR
which affects the urine production, the tubular fluid reabsorption and the compliance of
collecting system, especially of the renal pelvis. The second phase is characterized by a
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decrease in the RBF due to contraction of the afferent arteriole at the glomerulus by the
activation of the RAAS and TA2. The tubular and UP remain elevated in this phase as
consequence of the initial increase in RBF, but as time passes, the pressure in tubular and
collecting systems decreases because the GF ceases as the RBF diminishes.
All the aforementioned changes occur in the acute setting, and patients with a
contralateral healthy kidney usually do not exhibit clinical or classic biochemical signs of
AKI. Unfortunately, animal studies have documented pathological changes including
fibrosis in renal tissue during the first days and weeks of obstruction, despite a normal
contralateral kidney (Guerin, 2008; Nagle, 1978). Hou et al, after analyzing the efficacy
of micro-CT scans to detect structural changes during complete UUO in a murine model,
found histological fibrotic changes in renal tissue after 7 days of obstruction. Evidence of
tubular atrophy and interstitial presence of inflammatory cells were evident after two
weeks of obstruction (Hou, 2015). No human studies have evaluated the mechanisms of
renal atrophy after acute urinary obstruction, but it is accepted that these changes also
occur in humans.
In clinical practice, chronic hydronephrosis results from a more dynamic process, where
the obstruction is gradual and usually incomplete, a key factor that may decrease the
ureteral pressure and the subsequent hemodynamic response. Although, the evidence
suggests that obstruction of the upper urinary tract leads the cascade of inflammatory and
fibrotic mechanisms in renal parenchyma. Some models have been studied and will be
discussed later in this chapter.
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1.2.2 Pathophysiology of bilateral ureteral obstruction or
obstruction in a solitary kidney model
The model of bilateral obstruction or complete obstruction in solitary kidneys differs
from the unilateral model by the absence of a contralateral unit that filtrates and
eliminates the vasoactive substances that may affect the “triphasic response”. The
accumulation of biochemical mediators causes a transient increment in renal blood flow
with prolonged elevation in UP decreasing the eGFR. The absence of a normal
contralateral kidney precludes the elimination of inflammatory mediators, increasing the
inflammatory response, the cellular damage and the accumulation of waste products such
as urea and creatinine. These changes are acute and their clinical implications can be
catastrophic, requiring urgent management to relieve obstruction and avoid metabolic
complications related to renal failure. This topic is beyond the scope of this research
project, as we focused in those cases with subclinical AKI not requiring urgent
management.
The following figure is intended to integrate the functional, hemodynamic and
biochemical changes in unilateral and bilateral ureteral obstruction, which finally lead to
a cellular fibrotic response. We also show the specific time when the most common
markers of AKI are detected to demonstrate their relationship with the pathophysiologic
process of renal injury. The new AKI markers are released in the early phase of
obstruction, making them potential indicators of early renal injury.
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Phase

Unilateral
Obstruction

Bilateral
Obstruction

Time of
expression of AKI
marker

Acute phase
(1-2 hours)

⬆RBF to compensate ⬆ UP
keeping ≈ GFR

⬆RBF to compensate ⬆ UP
but GFR ⬇

NGAL, KIM-1, IL-18,
L-FABP

Mid phase
(2-5 hours)

⬇ RBF ⬇ GFR
⬆ UP
⬇ RBF ⬇ GFR

Later phase
(>5-24 hours)

⬇ RBF ⬇ GFR
⬆/ ≈ UP
Creatinine, Urea, Cys C

Chronic phase
(>24 hours)

⬇ RBF ⬇ GFR

Abbreviations: Cys C, Cystatine C; GFR, glomerular filtration rate; IL-18, Interleukin 18; KIM-1, Kidney Injury Molecule-1;
L-FABP, Liver-type Fatty Acid-Binding Protein; NGAL, Neutrophil Gelatinase-Associated Lipocalin; RBF, renal blood flow;
UP, ureteral pressure.

Figure 3: Functional changes following unilateral and bilateral obstruction and
markers of kidney injury (Adapted with information from Bellomo, 2012;
Campbell-Walsh, 2012; Loo 1988).

1.2.3 Partial ureteral obstruction
Some researchers investigating the deleterious effects of partial ureteral occlusion have
used neonatal animal models to evaluate the changes in cellular differentiation and
development (Sugandhi, 2014; Wen, 1998). Glomerular and tubular structures are
compromised and the overall renal function is affected. This process is likely similar to
what happens in newborn patients with prenatal hydronephrosis and posterior urethral
valves who have chronic kidney disease related to renal dysplasia.
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Animal models creating partial ureteral obstruction have found evidence of parenchymal
loss, peripelvic and interstitial fibrosis in the early phase (2-4 weeks) of unilateral
obstruction (Botto, 2011; Guerin, 2008). These findings show the deleterious impact on
long-term renal obstruction, even in models with incomplete obstruction. Interestingly the
degree of tissue damage did not always correlate with the grade of dilatation of the upper
tract. For these reasons, we believe that we should not rely only on the presence or
absence of hydronephrosis in the imaging studies of patients with stone disease to rule
out the existence of subclinical kidney injury.
Many research studies have focused on analyzing mechanisms to avoid apoptosis and
fibrosis in animal models with renal obstruction. Nitric oxide (NO), transforming growth
factor (TGF-β1), Tumoral Necrosis Factor-α (TNF-α) and other new biomarkers have
been implicated in renal remodeling. Some of these will be later discussed because their
expression during episodes of ischemia/obstruction has been used to identify patients
with a higher risk of poor outcomes, and are the current basis for timely AKI diagnosis.

1.3 Mechanisms of renal injury
Urinary obstruction causes a significant derangement in the mechanisms of urinary
concentration, and continuous obstruction causes cellular injury leading to tubular and
interstitial atrophy, fibrosis and cellular proliferation (Ito, 2004). Apoptosis is the main
pathway that leads to renal atrophy and chronic kidney disease (CKD), which is
principally established by glomerular sclerosis and interstitial fibrosis.
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Apoptosis is orchestrated by several intracellular and transmembrane signals involving
caspase enzymes and TNF-α pathway resulting in the release of intracellular proteins
with subsequent tubular cell death (Chevalier, 2009). Renal architecture is also affected
when acute inflammation augments the synthesis of metalloproteinases leading to fibrotic
changes.
The angiotensin pathway is a promoter of fibrotic changes by upregulating the expression
of cytokines that stimulate extracellular inflammation, such as TNF-α and TGF-β1. The
synthesis of extracellular matrix, mostly collagen fibers, and the signaling process to
recruit inflammatory cells contributes to the histological changes that decrease the
amount of parenchyma by destruction of the nephrons (Hewitson, 2009). Tubular atrophy
and interstitial remodeling also cause obliteration of postglomerular peritubular
capillaries, with a subsequent decrease in the GFR (Ito, 2004).
A similar biological pathway of renal fibrosis linked to ischemic injury is also exhibited
in cases of chronic obstruction. The interactions between inflammatory cells and
interstitial cells, besides causing fibrosis in tubular area, can cause de-differentiation into
mesenchymal cells or apoptosis of endothelial cells leading to renal ischemia (Chevalier,
2009). This process may be slow, but may explain the progressive kidney damage seen in
patients with chronic UUO.
As urologists we are interested in the grade and time course of obstruction because these
factors will impact the histological injury of the renal parenchyma and the long term
global renal function. Kerr in 1956 was the first to correlate the degree of injury with the
duration of obstruction. Vaughan evaluated the radiological and pathological appearance
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of unilateral obstructed renal units in dogs and found a remarkable recovery 4 weeks after
relieving the obstruction. In contrast, animals that had an obstruction longer than 7 weeks
however, did not have complete recovery (Kerr, 1956; Vaughan, 1971).
The extent and magnitude of the obstructive process and the degree of cell loss during the
inflammatory and fibrotic post-obstructive process play important roles in the recovery of
renal function. The duration of unilateral ureteral obstruction and the animal species
analyzed have been found to be determinants of renal recovery (Bander, 1985; Leahy,
1989; Vaughan 1973). Other factors such as level of obstruction, compliance of
collecting system, presence of infection, and integrity of lymphatic channels may affect
the final pathway for histological injury (Vaughan, 2004).
Upon relief of obstruction, not all of the mechanisms behind kidney injury will halt.
Progression of renal damage has been demonstrated in histological analysis in a rat study
after only 3 days of complete ureteral obstruction, despite normal renal blood flow or
GFR (Ito, 2004). Cochrane and colleagues developed a mouse model where UUO was
carried out for 10 days, and then were allowed to recover for a period of 1, 2, 4 or 6
weeks. Results showed a significant increase in the number of macrophages and collagen
fibers during the first weeks after obstruction relief with a decrease in the unilateral GFR,
however, animals that were sacrificed after 6 weeks had a decreased grade of fibrosis and
inflammation, but the eGFR of the affected unit was between 50-84% of the contralateral
side (Cochrane, 2005). This definitely may compromise the long-term renal function,
especially if we translate these findings to patients with medical conditions that
chronically affect renal function, like diabetes, hypertension or recurrent stone disease.
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The process of renal obstruction, either unilateral or bilateral, involves vascular,
hemodynamic, and humoral pathways which are intended to respond to the insult,
however these same complex mechanisms of renal restoration may contribute to
architectural alterations that accelerate nephron loss and subsequent CKD (Harrison,
2015).

1.4 Acute Kidney Injury
Acute kidney injury (AKI) is a broad term used to define a sudden decrease in the GFR of
both kidneys causing retention of waste products, such as urea and creatinine and
dysregulation of extracellular volume and electrolytes (Bellomo, 2012; Palevsky, 2014).
While this condition might be subclinical and may not be recognized by a medical
practitioner in asymptomatic patients with normal baseline renal function, alternatively it
might be life-threatening and considered as a risk factor for patient mortality in an acute
illness, like septic shock. The duration, severity, and baseline renal function will
determine if other metabolic anomalies will accompany the scenario. Recently, the term
AKI replaced the expression “acute kidney failure”, with the latter now reserved only for
severe kidney injury associated with the need for renal replacement therapy, such as
hemodialysis. AKI can be caused by three different mechanisms, which will be explained
below, and Figure 4 shows the most common causes of each.
•

Prerenal, refers to the clinical situation where the glomerular filtration mechanisms
are preserved and the dysfunction arises from a hypovolemic state, or renal blood
flow is reduced. Clinical examples include patients with AKI related to extensive
bleeding or septic patients where decreased vascular resistances diminish the renal
blood flow, and patients with cardiogenic shock. The physiological response to renal
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hypoperfusion involves vasodilation of the afferent arteriole and vasoconstriction of
the efferent arteriole in an attempt to keep an adequate blood flow for GF. If the renal
hypoperfusion is not reversed, ischemic insult to the tubules will occur which is
called Acute Tubular Necrosis (ATN).
•

Renal causes of AKI are the most common and involve a primary dysfunction within
the nephron. ATN is by far the most frequent cause of AKI in the emergency
department, being intimately related to prerenal disturbances, but some intrinsic and
extrinsic toxins and exogenous agents may cause direct tubular damage (i.e.
cisplatin, non steroidal anti-inflammatory drugs)

•

Postrenal causes are of particular interest to urologists because an appropriate and
timely treatment can prevent serious complications. These are related to acute
obstruction of the urinary system; and as previously explained the severity is
associated to the time of onset and bilateralism.

Acute Kidney
Injury - AKI

Prerenal

Renal

Postrenal

§ Hypovolemic shock –
hemorrhage
§ Congestive heart failure
§ Acute occlusion of renal artery

§
§
§
§

Acute glomerulonephritis
Interstitial nephritis
Acute tubular necrosis
Vasculitis

§ Upper urinary tract obstruction
§ Bladder-outlet obstruction

Figure 4: Common causes of AKI according to the specific cause.
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1.4.1 Definition and diagnosis
Different groups have defined AKI, and distinct classifications have been developed to
improve the threshold of detection and the quality of health care. The most common
schemes are the Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) and Acute
Kidney Injury Network (AKIN) criteria. Definitions are similar and are based on
creatinine levels, urine output and preferably require knowledge of baseline serum
creatinine of the patients (Bellomo, 2004; Mehta, 2007).
AKI is a diagnosis commonly encountered in the emergency department and the
Intensive Care Unit, with prevalence rates as high as 50-60% (Bouchard, 2015). Patients
with AKI usually present clinical manifestations from other systems associated with an
underlying disease. Diagnosis of AKI is made after biochemical test are ordered, such as
serum blood nitrogen urea and creatinine, or clinically by measuring the urine output.
Both parameters are functional and do not reflect the histological renal injury.
The RIFLE criteria, proposed by the ADQI group (Acute Dialysis Quality Initiative),
graded renal injury in three levels and determined two different outcomes accordingly. It
uses the serum levels of creatinine or the urine output of patients over time to grade the
level of injury (Bellomo, 2004). The AKIN criteria is also commonly used in the acute
setting and employs similar parameters as the RIFLE classification, but addresses only
one outcome, the need for renal replacement therapy (Mehta, 2007). As Figure 5
demonstrates, RIFLE definitions depend on a proportional increase of serum creatinine or
oliguria for more than 6 hours. AKIN also defines Stage 1 injury as an increase creatinine
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of ≥ 0.3 mg/dl. These definitions obviously do not fit all cases and reveal the need for
more specific and practical markers of kidney injury.

RIFLE Criteria

AKIN Criteria

Risk

⬆Cr x 1.5,
eGFR decreases > 25%

UO < 0.5 ml/kg/hr (6 hrs)

⬆Cr x 1.5,
⬆ ≥ 0.3 mg/dl in Cr

UO < 0.5 ml/kg/hr (6 hrs)

Stage 1

Injury

⬆Cr x 2,
eGFR decreases > 50%

UO < 0.5 ml/kg/hr (12 hrs)

⬆Cr x 2

UO < 0.5 ml/kg/hr (12 hrs)

Stage 2

Failure

⬆Cr x 3,
eGFR decreases > 75%,
Cr ≥ 4 mg/dl

UO < 0.3 ml/kg/hr (24 hrs)
Anuria x 12 hrs

⬆Cr x 3,
Cr ≥ 4 mg/dl with ⬆ ≥ 0.5
mg/dl

UO < 0.3 ml/kg/hr (24 hrs)
Anuria x 12 hrs

Stage 3

Loss

Complete loss of renal function for > 4 weeks

Patients requiring Renal Replacement Therapy are
considered to have met Stage 3

Loss

EndStage

End Stage Renal Disease > 3 months

End Stage Renal Disease > 3 months

EndStage

Abbreviations: Cr, Creatinine; eGFR, estimated glomerular filtration rate; UO, urine output.

Figure 5: RIFLE and AKIN criteria of acute kidney injury (Adapted from Bellomo,
2004 and Mehta, 2007).

Serum Creatinine
Creatinine (Cr) has been considered the gold standard for global kidney function
evaluation. The absolute value might be affected by the rate of production, the hydration
status of the patient and the type of creatinine assay. Moreover, abnormal serum levels
are only observed when more than 50% of the glomerular filtration rate is affected. In
unilateral kidney injury in the presence of a normal contralateral unit, creatinine may not
be elevated at all. One other important drawback of serum creatinine measurement is the
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need for a baseline value to compare with and to define AKI according to the appropriate
classification. Because it can take more than 24-48 hours to increase in the setting of AKI
it loses the diagnostic performance when there is a sudden change in the eGFR. In
summary, by using serum creatinine as a marker of AKI we are delaying the diagnosis by
identifying the functional consequence of the kidney damage, and not the injury by itself.
Cystatin C
Cystatin is a protease inhibitor produced by almost all human cells in a constant rate, it is
filtered by the glomerular membrane and seems to be unaffected by factors other than the
GFR. It has been proposed as an alternative option from serum creatinine to assess renal
function and predict mortality and cardiovascular events. Several population-based
studies have evaluated its role in the detection and prognosis of CKD finding a good
association with the eGFR and better predictive rates for ESRD and survival than serum
creatinine (Ingelfinger, 2013; Shlipak, 2013). Cystatin C has also been useful to detect
subclinical AKI in different cohorts of ICU patients (Gaygisiz, 2016) but its role in
urological patients has been inconsistent, and it has not been associated with
hydronephrosis (Karakus, 2016; Madsen, 2012). Moreover, it may reflect a functional
consequence of the renal damage, instead of a true injury.
Urine output
Low urine output, also called oliguria (< 0.5 ml/kg/hr) is considered a diagnostic
parameter for AKI diagnosis (Figure 5), and can also be monitored to evaluate the
patient’s response to therapeutic maneuvers. Change in urine output is one of the first
signs of kidney injury and it appears even before biochemical changes. Prerenal causes of
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AKI are characterized by anuria or oliguria, while urine output in renal and postrenal
situations vary from anuria to polyuria.
Several observations have been raised about the clinical utility of these definitions and
the need of individualization in specific situations. The current recommendation is to use
the first available serum creatinine and avoid using a historical value (Fliser, 2012). Other
authors suggest the use of urine output by ideal body weight. These limitations come
from the absence of evidence regarding the ideal cut-off value to determine the different
stages of AKI, independently of the criteria used.
New evidence suggests that, these criteria may be replaced by biomarkers of renal tubular
injury, such as KIM-1 and NGAL (Siew, 2012). Until further evidence proves the
positive clinical impact of these new methods, we will continue to use the
aforementioned criteria to detect patients with kidney injury.
Urine protein and urine protein-creatinine ratio
Proteinuria is a well-defined effect of glomerular disease and has been used to determine
and monitor the grade of injury in different clinical situations. It may reflect a decreased
capacity of reabsorption at the level of renal tubules, implicating tubular or interstitial
damage, but an increased protein production by systemic disease (e.g. multiple myeloma)
can also cause proteinuria by an overflow mechanism. This parameter is recommended
for detecting and monitoring proteinuria in patients with CKD, but it not the best strategy
to evaluate AKI because it directly relies on creatinine excretion, which is usually
diminished in patients with AKI (Nguyen, 2009).
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1.4.2 Post renal causes of AKI
Urological patients with AKI are seen in less than 10% of the hospitalized cases, but the
prompt diagnosis with early relief of obstruction in these patients can prevent lifelong
kidney damage (Caddeo, 2013). Table 1 already described the most common causes
associated with upper urinary tract obstruction. As urologists we face AKI in patients
with bilateral hydronephrosis, most commonly caused by bladder outlet obstruction or
bilateral obstructive stone disease. On the other hand, unilateral hydronephrosis is usually
not accompanied by AKI, except in patients with chronic kidney disease or with a nonfunctioning contralateral renal unit. Despite this, the obstructive process may initiate the
cascade of metabolic mechanisms that could lead to renal fibrosis.
As previously discussed, UUO is also associated with the initiation of injury mechanisms
that lead to fibrosis, cellular apoptosis and chronic kidney damage. The usual clinical
parameters of kidney function are insufficient to detect unilateral kidney damage in
patients with a contralateral normal kidney.
We focused our research on the evaluation of AKI markers in patients with stone disease
and hydronephrosis. We planned to also include patients with UPJO, which is a specific
condition of upper urinary tract obstruction that is usually not associated with other
inflammatory conditions.
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1.4.2.1

Renal stone disease

Nephrolithiasis is one of the most common urological causes of emergency department
visits; patients usually seek medical evaluation after an episode of renal colic. Initial
evaluation is performed to determine the diagnosis, and imaging studies are completed to
define the appropriate management, which depends on the clinical manifestations,
association with infectious processes, and comorbid conditions. Several studies have
shown an increased risk of CKD and ESRD in patients with nephrolithiasis (Keddis,
2013).
Patients requiring urgent management usually have a double J stent or nephrostomy
placed after being evaluated in the emergency department. Those without an urgent
indication for treatment, despite the grade of obstruction, are seen in an outpatient basis
to determine the need for further management. Patients with small ureteric stones
(<7mm) may be offered medical expulsive therapy to promote the passage of the calculus
avoiding an invasive procedure (Miller, 2007; Nakada, 2015). Approximately 15-20% of
the patients require an invasive management, either emergent decompression of the
urinary tract or definitive therapy: shockwave lithotripsy (SWL), ureteroscopy (URS) and
percutaneous nephrolithotomy (PCNL) (Nakada, 2007).
Specific indications for stone management are described in the literature (Preminger
2007; Türk, 2015), and are beyond the scope of this study, but to summarize, large kidney
stones (usually > 2cm) are treated with PCNL, smaller kidney stones and ureteric calculi
required SWL or URS. For the purpose of this study, we did not evaluate patients who
had SWL because several studies have found an increase expression of AKI markers
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during this treatment, which is related to injury of the renal parenchyma and might affect
the interpretation of our results (Nader, 2013; Nikoobakht, 2006).

1.4.2.2

Ureteropelvic junction obstruction and ureteric
stricture

Ureteropelvic junction obstruction (UPJO) is a urological disease encountered in the
pediatric and adult populations characterized by a congenital anatomical anomaly that
impairs the flow of urine from the renal pelvis to the proximal ureter. The obstruction
results from an aperistaltic segment of ureter or the presence of abnormal blood vessels
that cause extrinsic compression of the upper ureter. Imaging studies usually reveal a
severely dilated renal pelvis with an abrupt transition to a normal size upper ureter. Some
patients may have secondary renal calculi associated with long-standing obstruction,
although these stones are typically not the cause of obstruction.
Regardless of the cause and the age at the time of diagnosis, the clinical assessment
should determine if the mechanical obstruction affects the dynamic flow of urine to the
lower urinary tract, which means there is a functional repercussion to the renal unit. A
diuretic renal scan is considered the gold standard to determine the presence of functional
obstruction. A flat curve and a clearance half-life of the radiotracer > 20 minutes in the
renography scan is considered diagnostic of a functional UPJO (Khan, 2014). Treatment
of UPJO is warranted to relief symptomatic episodes of pain, infection but mostly to
avoid further deterioration of the renal function. The best treatment option is a minimally
invasive pyeloplasty, performed by either a laparoscopic or robotic approach and it is
associated with a success rates greater than 90% (Khan, 2014). Equivocal cases with
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radiotracer half-life of 10-19 minutes were not historically considered to have functional
obstruction, and clinical observation was warranted. Recent literature suggests that
pyeloplasty provides adequate functional results (Ozayar, 2015). Postoperative follow-up
includes a diuretic renal scan to evaluate the split renal function and rule out restenosis of
the recently created ureteropelvic anastomosis.
Patients with hydronephrosis caused by nephrolithiasis or UPJO obstruction are ideal
candidates to evaluate the impact of urinary tract obstruction on urinary AKI markers
levels. They have preoperative radiological evaluation, which is used to plan the
intervention and to determine the presence and grade of hydronephrosis. Renal function
assessment is always made during the initial evaluation at the initial urological
consultation. An invasive procedure is performed (URS/PCNL/pyeloplasty) to remove
the cause of obstruction and follow-up studies determine the success of the intervention.
The standard of care will allow the collection of urine samples and correlate clinical,
radiological and biochemical findings with the levels of these markers in this set of
urological patients.

1.5 Diuretic renography
Diuretic renography is a nuclear non-invasive study which provides a measurement of the
renal function in each of the renal units, while detecting the presence of obstruction in the
upper urinary tract. This test allows discrimination of the urinary tract system dilation
without obstruction, from true physiological obstruction. It is based on the principle that
the injected radiotracer in freely filtered and accumulated in the renal collecting system,
and in the absence of urinary tract obstruction the diuretic increases the urine flow
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clearing the tracer from the renal silhouette. Tracer activity along with time are plotted in
a X-Y graph (Time-activity curve), which is visually evaluated with the aid of
computerized software to determine the clearance half-time of the radiotracer, less ten
minutes is considered normal. Several factors may play an important role in obtaining
and interpreting the results, like hydration status, administrated diuretic dose and time,
previously determined region of interest (ROI) and the method of evaluation
(computerized vs visual) (Karam, 2003; Sarkar, 1992).
In clinical practice, a half-life clearance > 20 minutes after the diuretic dose is considered
diagnostic for obstruction. Depending of the site and cause of obstruction, appropriate
management should be tailored according to patient’s conditions. However, some patients
show clinical signs and symptoms of chronic obstruction with a diuretic renogram that
fails to show obstruction (1/2 life clearance 10-20 minutes). There is no agreement about
the most appropriate treatment, being observation, temporal stent placement or surgery
accepted management strategies. Despite that current treatment indications are based on
the renogram findings of obstruction, there is recent evidence that patients with equivocal
UPJO may benefit from minimally-invasive treatment, by preserving long term renal
function (Ozayar, 2015). This is also another argument that reflects that our current
methods for urinary tract obstruction diagnosis are not 100% accurate, and need to be
revised to improve patients’ health care.

1.6 Markers of Acute Kidney Injury
Since it was first introduced, over 80 years ago, creatinine has been considered as an
accurate parameter to determine global renal function. Despite its widespread use,
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creatinine is considered a poorly sensitive marker in the acute setting, mainly because it
may take 48-72 hours after the renal injury for serum levels to rise. It is usually measured
in conjunction with serum urea, which accumulates in the blood stream due to ineffective
glomerular function.
Both serum parameters do not reflect the renal damage in “real time”. Glomerular
filtration needs to decrease to more than 40-50% to show increments in baseline levels,
making them insensitive for detection of acute kidney injury (Siew, 2011). Moreover,
slight injury to renal parenchyma, which may be presented in cases of incomplete or
unilateral obstruction, may not be detected by these standard tests.
Despite the improvements in the management of acutely ill patients, the mortality and
morbidity associated with AKI has not decreased during the last two decades (Chertow,
2005). One of the main reasons is that serum creatinine reflects renal function but not
real-time damage (Nguyen, 2007: McWilliams, 2014). Contrary to what has happened in
myocardial infarction, where troponins are very sensitive indicators of abnormal
myocardial perfusion making earlier interventions effective to improve patients’
outcomes, the diagnosis of AKI is delayed by the use of serum creatinine. This
shortcoming with serum creatinine has stimulated research into identifying more accurate
markers of renal function (Siew, 2011).
Recently, some translational research reports suggested the promising role of proteins
that are upregulated after kidney injury (Bonventre, 2014). Initially, animal experiments
revealed good specificity and sensitivity of these molecules to detect renal damage after
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ischemic or nephrotoxic insult (Siew, 2011), and human cohort studies have evaluated the
diagnostic performance of several biomarkers in AKI and CKD (Hsu, 2015).
In fact, the American Society of Nephrology designated AKI biomarkers research as a
top priority, leading to the identification of at least 20 different potential markers. A
biomarker is a specific feature that can be measured and indicates a biological process
(Atkinson, 2001). According to several studies and expert opinion, the most promising
are NGAL, KIM-1, Interleukin-18 (IL-18), cystatin-C, liver-type fatty acid-binding
protein (L-FABP), glutation S-transferase (GST) and N-acetyl-B-D-glucosaminidase
(NAG). Clinical studies have analyzed their particular role in predicting outcomes of
critically ill patients (Zappitelli, 2007), risk of AKI in patients after cardiac surgery
(Perrotti, 2015), chronic renal injury in diabetic patients (Sabbisetti, 2014), contrastinduced nephropathy (Tong, 2015), and renal transplant patients with graft dysfunction
(Alachkar, 2011; Malyszko, 2010).
These proteins are now considered as biomarkers of AKI; they can be measured in blood
and urine and have shown a better correlation with the effects of AKI than serum
creatinine (Siew, 2011). The detection of these molecules relies in three different
mechanisms that may provide signs of renal injury in an opportune fashion, showing
more sensitivity to AKI than serum creatinine:
•

Structural proteins excreted during initial tubular damage

•

Molecules not reabsorbed after tubular dysfunction

•

Protein production after specific genes are upregulated during acute tubular injury
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The third mechanism has been studied the most, with KIM-1 and NGAL as the more
commonly evaluated biomarkers in basic and clinical studies (Cost, 2013; Karakus, 2016,
Urbschat, 2014).
Multiple questions are still remaining, specifically about the clinical usefulness of these
proteins, especially in urological patients. For example, KIM-1 has been catalogued as a
marker of injury, but also some evidence exists in animal studies about a possible antiinflammatory effect (Yang, 2015). On the other hand, NGAL can also be secreted by
activated neutrophils, which may reduce the sensibility for AKI detection in patients with
inflammatory conditions, other questions include:
•

Is the renal obstruction associated with subclinical acute kidney injury?

•

Does the hydronephrosis grade correlate with the extent of renal injury measurable by
AKI markers?

•

Are any of these proteins a reliable marker of hydronephrosis?

•

Can we use these biomarkers in urological patients to assess other systemic
conditions that may cause renal injury?

McWilliam and colleagues reported the reference intervals for KIM-1 and NGAL in
healthy children analyzing more than 250 samples from UK and USA being an essential
step for further use of these biomarkers in clinical settings, such investigations have not
been performed in adult populations (McWilliam, 2014). In order to control the variations
in hydration status and urine production, urinary biomarkers are usually normalized to the
urinary levels of creatinine.
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Our research was centered in the evaluation of KIM-1 and NGAL, which can be
measured in urine, and are mostly expressed in renal tissue. We will present a summary
of the most important information related to these two biomarkers.

1.6.1 KIM-1
Initially named TIM-1(Tissue Injury Molecule-1), this marker was identified using
mRNA analysis after renal ischemic injury in rats. It is a transmembrane protein
expressed in small amounts in normal kidney, but highly replicated in the proximal
tubular epithelial cells after an ischemic insult, having a potential role in the regeneration
of the normal function of the tubular cells (Ichimura, 1998). Recently, Yang and
colleagues proposed an antiinflammatory effect by enhancing the phagocytic process and
protecting the kidney from AKI (Yang, 2016).
KIM-1 has a immunoglobulin-like domain, specifically located in the apical membrane of
proximal tubular cells. Histological analysis has revealed a predisposition for expression
in the proximal renal tubule. The ectodomain is stable and appers in the urine after renal
insult. It has been qualified by the Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) for preclinical assessment of nephrotoxicity
(Bonventre, 2014; Dieterle, 2010).
Several theories have been evaluated in recent years to elucidate the overexpression of
KIM-1 after renal injury. Because it is highly expressed in tubular epithelium after cell
injury, KIM-1 may play a role in the regeneration of epithelial cells by facilitating their
restoration, but other studies have shown that KIM-1 has a renoprotective effect, by
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facilitating the apoptotic response of injuried cells (Bonventre, 2014). Despite the
evidence regarding the possible protective effect of KIM-1, chronically injured cells also
express KIM-1 on their surface augmenting the interstitial fibrotic process, Whether the
expression is mainly affected by acute or chronic injury, a consensus exists regarding the
limited expression in healthy kidney tissue.
Animal studies have demonstrated an increased expression of urinary KIM-1 after renal
insult. A rat model experiment found an increased expression of tissue and urinary KIM1 in animals after cisplatin-induced nephrotoxicity; it was the most sensitive marker,
correlated with the progression of kidney lesion and was observed before histological
injury (Vinken, 2012). Vaidya and colleagues found a significant increment in urinary
KIM-1 levels after bilateral renal ischemic injury in rats, while serum creatinine remained
within normal limits (Vaidya, 2009).
Several clinical studies have demonstrated the relationship between KIM-1 expression
and chronic and acute kidney injury. It has been found to be a good predictor of
postoperative AKI in patients undergoing cardiac surgery, even before serum creatinine
elevation (Han, 2009). Sabbisetti and collegues found that elevated serum KIM-1 levels
predicted the rate of eGFR and the risk of developing ESRD in Type 1 diabetic patients
(Sabbisetti, 2014).
Our Urology department investigated the expression of KIM-1 after shockwave
lithotripsy in kidney stone patients. We demonstrated higher urinary KIM-1 levels in
stone disease patients compared to healthy subjects, and we noted a significant increment

30

in the urinary levels hours after the lithotripsy suggesting transient renal tissue injury
caused by the SWL (Nader, 2013).
Some case-control studies have found elevated urinary levels of KIM-1 in patients with
obstructive nephropathy compared to controls. Wasilewska and collegues compared
pediatric patients with UPJO to patients with mild hydronephrosis and healthy children
and found higher preoperative KIM-1 levels in those with UPJO, decreasing up to 75%
three months after the pyeloplasty (Wasilewska, 2011). Another study from China,
evaluate the expression of KIM-1 and NGAL in patients with AKI and obstructive
nephropathy and found a good predictive value to diagnose AKI, furthermore the same
group demonstrated that postoperative levels of these markers were predictors of renal
function at one year measured by serum cretininea, albeit radiological information was
missing and patients had severely impared renal function (Xie, 2014; Xue, 2014).

1.6.2 NGAL
Neutrophil gelatinase-associated lipocalin (NGAL, lipocalin 2) is a 178-aminoacid
polypeptide chain which belongs to the lipocalin superfamily, and was originally isolated
from neutrophils (Kjeldse, 1993). Different molecular forms have been described and will
be discussed later, but several clinical studies have concluded it is a sensitive biomarker
of AKI (Mårtensson, 2014). Most of the information regarding the origin and
biochemical role comes from animal studies, and several theories have been created to
explain its function after renal injury.
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Zappitelli and collegues found urinary NGAL to be useful marker of AKI severity in
critically-ill children (Zappitelli, 2007). Kuwabara investigated urinary and serum
expression of NGAL in mice with obstructive nephropathy. Unilateral ureteral
obstruction causes a 100-fold increment in NGAL synthesis in distal nephrons, which
suggests damage to tubular epithelia (Kuwabara, 2009). Other AKI studies have
confirmed the increased synthesis in tubular epithelia, but models of chronic injury have
found that urinary NGAL also correlates with the eGFR.
NGAL is not only secreted in renal tissue, it has also been isolated in hepatocytes and
immune cells, being involved as part of the innate response against gram-negative
bacteria. In fact, it was initially discovered in the immune response during bacterial
infections, because it binds to siderophores for iron transport and prevents the growth of
bacteria dependant on iron supply. Xu and collegues compared NGAL levels in patients
during an acute bacterial or viral infection and found a positive correlation of its levels
with a bacterial infection (Xu, 1995). Genetically modified mice lacking both NGAL
gene copies have been found to have an increase risk in Escherichia coli infections
(Berger, 2006), and a recent small clinical study demonstrated that pediatric patients with
recurrent UTI have decreased urinary NGAL levels compared to patients without
recurrent UTI (Forster, 2014). Recent studies have address the prognostic value of plasma
NGAL (Total NGAL) as a marker of systemic inflammatory response symptoms (SIRS)
and sepsis, it was found as a predictor of mortality and multiple organ dysfunction
(Wang, 2015). NGAL has been evaluated after renal ischemic injury: van den Akker et al
found that serum NGAL was a good predctor of delay graft function after kidney
transplantation. A small prospective cohort study patients undergoing partial
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nephrectomy failed to show postoperative urinary NGAL as a predictor factor of renal
injury (Sprenkle, 2013; van den Akker, 2015). Whether NGAL is most specific as a
marker of systemic inflammatoion or renal injury remains unanswered (Martensson,
2014).
Differences in the expression of NGAL in several clinical situations are explained by the
presence of different molecular forms of NGAL in urine and plasma. Cai et al analyzed
urine samples of patients after cardiac surgery, patients with UTI and in incubated HK-2
(human kidney epithelial) cells by using Western blot analysis they determined the origin
of the 3 molecular NGAL forms (Cai, 2009). The 21-25-kD monomer was primary
secreted by HK-2 cells and to some extent by the activated neutrophils, and may reflect
the severity of tubulointestitial damage (Nickolas, 2012). The 45-kD disulfide-linked
homodimer was secreted by neuthrophils and the 135-kD heterodimeric, conjugated with
gelatinase, also secreted by ephitelial cells, found in small quantities only (Glassford,
2013; Nickolas, 2012).
Their findings were supported by the discovery of elevated levels of urinary Monomeric
NGAL in patients with AKI after cardiac surgery, while patients with UTI, exhibited an
increased level of the dimeric form. Authors also found differences in the specificity of
the antibody epitope of both forms, which was used to develop specific essays for each
molecular form.
The vast majority of published studies about NGAL include the use of essays with some
kind of cross-reaction between the monomeric and homodimeric form. This could explain
the differences in clinical performance of the test, and the contradictory results.
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Moreover, multiple studies about AKI excluded patients with conditions that may
interfere with the expression of this marker, such as stone disease. For example,
Holzscheiter confirmed the role of NGAL as a promising tool to detect tubular injury but
it was influenced by the grade of leukocyturia (Holzscheiter, 2014).
Nickolas and collegues evaluated the relationship between urinary Monomeric NGAL
measured by immunoblot and the histological evidence of tubulo-intestitial damage in
patients with CKD. Their findings support the theory that Monomeric NGAL reflects
tubular damage. They found a higher correlation with tubular athrophy and intestitial
fibrosis, although Monomeric NGAL did not correalted with leukocyte infiltrate or
mesangial proliferation, suggesting a better association with chronic rather than acute
processes (Nickolas, 2012).
Mårtensson and colleagues were able to characterize the expression of Monomeric
NGAL by renal epithelial cells from the homodimeric form secreted by neutrophils using
two different ELISA assays (Mårtensson, 2012). Recently, a human monomeric-specific
NGAL ELISA kit was made commercially available (Bioporto, Hellerup, Denmark), and
showed <1% cross-reactivity with the homodimer form. This test improves the ability to
detect Monomeric NGAL, which in the absence of inflammatory conditions could be
mainly released by renal tubular cells (Bangert, 2012).

1.6.3 Other biomarkers
Some other molecules have been investigated in basic and translation research as
potential markers of kidney injury. Animal and human studies have shown contradictory
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results regarding the expression of cystatin, B2-microglobulin, interleukin-18,
osteopontin and liver-type fatty acid-binding protein (L-FABP). We therefore elected to
study the two markers showing most promise, KIM-1 and NGAL.
Despite the recent investigations, there was a need to prospectively evaluate the role of
these markers in urological patients with urinary tract obstruction and analyze their
expression considering the grade of obstruction and the presence of inflammatory
conditions, such as stone disease or ureteric stents. Similarly, the use of a novel assay to
determine the specific expression of Monomeric NGAL might aid in the evaluation of
AKI in urological patients who usually suffer inflammatory conditions in the urinary tract
that may affect the levels of NGAL. We believe our study will provide sufficient
information to determine if these molecules are useful in the evaluation of urological
patients.

1.7 Hydronephrosis
The term hydronephrosis is an anatomical denomination commonly used to describe
dilatation of the renal pelvis and/or calyces (Cho, 2007; Ito, 2010). Hydronephrosis is not
a synonym of obstruction, but is usually associated with it, except in cases of
vesicoureteral reflux, congenital megaureter or in patients with acute pyelonephritis
accompanied by a non-peristaltic ureter, as we previously discussed. It is a radiological
diagnosis, usually made after a renal ultrasound or a CT scan. In clinical practice it is
commonly accepted that the grade of hydronephrosis correlates with the grade of
obstruction, although this is just a supposition, because diuretic renogram is required to
determine the presence and grade of obstruction.
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The most acknowledged classification for hydronephrosis comes from the Society of
Fetal Ultrasound (SFU), which uses coronal and axial views of abdominal ultrasound to
assess the aspect of the renal parenchyma and the collecting systems (Fernbach, 1993).
This classification has been generalized and used as standard for adult population studies.
Cho and Ito described a similar hydronephrosis scale using CT findings in patients with
upper urothelial carcinoma to predict aggressiveness of the disease (Cho, 2007; Ito,
2010). The following table correlates both classifications:

Table 2. Grading of hydronephrosis according to SFU and CT criteria (Adapted
with permission from Fernbach, 1993, and Ito, 2011).
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In clinical practice, and according to the treatment guidelines for stone disease, only the
cases associated with septic processes and severe renal impairment are treated in an
urgent fashion (Preminger, 2007; Türk, 2014). Most of the patients with stone disease and
hydronephrosis have to wait weeks to months to receive definitive management. These
patients have an increased risk to suffer “subclinical” renal injury, because creatinine
levels are within normal limits, but the deleterious pathophysiologic process of
obstruction lasts until the obstruction is mitigated.
Another important factor that is difficult to extrapolate to clinical practice is the
possibility of having a partial or a complete ureteral obstruction. The grade of
hydronephrosis does not always correlate with the grade of obstruction. Several other
factors play an important role, such as hydration status, split renal function, and time of
onset. Complete obstruction of urine flow through the ureter might be accompanied by
urine flow into venous or lymphatic systems. Whether this affects the pathophysiology of
obstruction is not yet determined, but will probably be negligible.

1.8 Charlson comorbidity index (CCI)
The Charlson Comorbidity Index is a commonly used categorization that was described
in 1987 to grade comorbid conditions, which may affect the mortality of the patients in
longitudinal studies. It is widely used in the medical literature to evaluate the most
significant comorbidities that may affect the expectancy of life of the patients. Initially
included patient’s age and 19 different conditions, it was recently updated to include 23
items that received a score, to predict the 10-year survival. CCI has been validated and
accepted to describe patients’ comorbidities (Charlson, 1987; Charlson, 2008). We
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planned using this index to determine and compare the baseline comorbidities of the
patients.

1.9 Purpose of the study
This study will analyze the role of 3 AKI markers in urological patients: KIM-1, Total
and Monomeric NGAL. To the best of our knowledge, there are no published studies
describing the different isoforms of NGAL in urological patients. The main objective of
our research is to determine the urinary levels of KIM-1, Total and Monomeric NGAL,
before and after treatment in patients with urinary tract obstruction caused by intrinsic
ureteral obstruction or stone disease. The results of this research may help design a
larger multicenter study to assess the cost and time for diagnosis and follow-up of
patients with hydronephrosis related to UPJO or stone disease. Additionally, we will be
able to detect if patients with hydronephrosis due to obstruction and normal kidney
function, according to serum creatinine, also have subclinical AKI as shown by an
increase expression of urine markers.
If we prove our hypotheses to be correct, urinary AKI biomarkers may aid in the
diagnosis and discrimination of patients with obstruction (caused by stone or by UPJO)
and kidney injury with the ease of a simple urine test. Our results may help reduce the
reliance on imaging that is costly and may be associated with ionizing radiation
exposure. Furthermore, overall results will provide information about the safety of
delaying some interventions in patients with hydronephrosis without urinary tract
obstruction. Moreover, a urine-based test that could be employed at the point of care
might permit more timely intervention. These results may offer evidence regarding the
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impact of stone disease on the urinary levels of AKI and might give useful information
about the inclusion of urologic patients in large trials for AKI evaluation through
urinary markers analysis.
Our research project is intended and designed to evaluate the levels of the most
commonly investigated urinary markers in patients with unilateral upper urinary tract
obstruction. We expect to assess the following central hypothesis:
a. Baseline urinary levels of KIM-1 and Monomeric NGAL will be statistically
significantly higher in patients with unilateral renal obstruction caused by
either the presence of a urinary stone or by an ureteric stricture compared to
urinary levels after the treatment of obstruction.
Secondary hypotheses to be considered are:
a. KIM-1 and Monomeric NGAL will be statistically significantly different
between patients with and without obstruction
b. KIM-1 and Monomeric NGAL levels will be positively correlated with the
the grade of hydronephrosis and the overall kidney function measured by the
eGFR.
c. Monomeric NGAL will have a better correlation with obstruction and renal
function than Total NGAL
We expect that patients with hydronephrosis due to obstruction will have higher levels of
KIM-1 and Monomeric NGAL compared to healthy subjects and to patients with nonobstructing stone disease.
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Additionally, we plan to determine if patients with hydronephrosis and normal kidney
function have subclinical AKI as shown by an increased expression of urinary
biomarkers. If we prove our hypotheses to be correct, urinary AKI biomarkers may aid in
the diagnosis and discrimination of patients with hydronephrosis as to the presence or
absence of physiological obstruction with the ease of a simple urine test. These results
may also provide evidence regarding the impact of stone disease in the urinary levels of
AKI.
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2 Study design
This prospective cohort study was planned to observe the clinical course of patients with
unilateral renal obstruction causing hydronephrosis due to stone disease or intrinsic
ureteral disease, and to explore the expression of KIM-1, Total and Monomeric NGAL
within the usual standard of care. We followed the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) guidelines (von Elm, 2008;
Appendix 1) and the clinical study was approved by the Western University Health
Science Research Ethics Board (Appendix 2).
Our main objective was to determine the urinary levels of KIM-1 and NGAL (Total and
Monomeric isoform), before and after treatment, in patients with hydronephrosis caused
by intrinsic ureteral obstruction or stone disease. We chose these sets of patients for two
reasons: Stone disease is the most common cause of upper urinary tract obstruction and
affects many patients. Patients with intrinsic ureteral obstruction comprise a special
situation where diagnosis and follow-up may be challenging with conventional imaging,
and require the use of renography for diagnosis and follow-up. The potential impact of
our results could therefore be very relevant.
Additionally, by including patients with obstruction without kidney stones and patients
without obstruction and kidney stones we would know whether there are differences in
the expression of Monomeric NGAL. Inflammatory conditions are thought to cause an
increment in the Total NGAL concentration, but theoretically will not significantly affect
Monomeric NGAL levels. We also aim to assess the expression of these markers in
patients with stone disease and no hydronephrosis and in a healthy control group because
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the medical literature does not have clear evidence about the pattern of expression of
these proteins in these populations.
All this information will allow a comprehensive evaluation about the clinical utility of
these markers in urological patients. The study design will facilitate the evaluation of
urinary marker expression in a longitudinal approach: when obstruction is present, and
after the obstruction is relieved. Appropriate clinical and radiological follow-up will
strengthen the results and several analyses will be performed to explore the role and the
factors affecting the expression of these markers in urological patients.
We have already stated that our primary focus will be to assess the expression of KIM-1
and both Total and Monomeric NGAL in patients with hydronephrosis, but we also plan
to analyze the differences in the expression of these urinary markers in patients with
inflammatory stone disease and indwelling ureteric stents, where an inflammatory
response may be present. We hypothesize that KIM-1 and Monomeric NGAL will be
elevated in patients with hydronephrosis. We also hypothesize that these two markers
would correlate to the grade of hydronephrosis and overall renal function. In order to
complete the planned analyses, this cohort study investigated 3 different groups:
1. Patients with hydronephrosis
2. Patients with stone disease and no hydronephrosis
3. Control group of subjects without stone disease or hydronephrosis
Based on the standard of care in our urological practice, we were able to prospectively
evaluate the concentration of urine markers in patients during their treatment and followup. This gave us different patient populations that were evaluated independently and

42

compared among them longitudinally. Stone disease diagnosis and follow-up require
imaging studies, such as Computed Tomography scan (CT scan) or a renal ultrasound
which are usually performed as part of the standard of care by the treating urologists.
This information was used to determine the presence or absence of hydronephrosis to
include them in one of our 2 studied groups of patients and evaluate the stone
characteristics.
A preoperative urine sample was collected, along with two postoperative urine samples.
Patients who required a double J stent placement during the surgical procedure, were
followed during the two succeeding appointments to evaluate clinical and radiological
parameters and collect urine samples. During the third visit, patients would no longer
have a ureteric stent, and the levels of the urine markers should not be affected by the
stent, but might be affected by the presence of residual stones.
We anticipated that some patients with ureteral stones, while waiting for the surgical
procedure could have spontaneously passed the stone. These patients were asked to give a
second urine sample during the next clinic visit, after stone passage in order to complete
the study. Likewise, in very selected cases, patients did not require ureteric stent
placement after the surgical management of their stones and they completed the followup after only one postoperative visit.
The design of this study allowed a comparison of urine marker levels during the initial
urological evaluation between two groups of patients and the control group. As there is
some evidence suggesting a possible influence of inflammatory conditions on AKI
markers expression, we decided to evaluate biomarker concentration using the third urine
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sample, when patients do not have stents and the burden of residual stones is lower.
Furthermore, we were able to explore if urinary markers expression correlates with the
grade of leukocyturia. The following diagram illustrates the recruitment and flow of
patients’ assessment along the study:

Figure 6: Patient recruitment algorithm.
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2.1 Sample size calculation
No studies exist in the literature about the role and urine levels of Monomeric
NGAL in urological patients. The information available came from trials performed
in ICU (Intensive Care Unit) patients with sepsis and AKI. They used two different
assays and reported median urinary concentrations of monomeric NGAL between
145-350 ng/mL (Martesson, 2012; Bangert, 2013). This data cannot be used to
calculate an appropriate sample size because our study involves patients in a
different clinical scenario and who might have subclinical AKI, expecting lower
biomarker levels. We propose an exploratory analysis for the Monomeric NGAL
isoform, therefore the calculation was based on previous urological literature on
KIM-1.
As we previously discussed, literature about these biomarkers in urological patients
is sparse, and only few studies longitudinally analyze KIM-1 urinary concentration
in pediatric patients. According to previous data about the adjusted KIM-1
concentration in urine from our centre (Fahmy, 2013), we were able to estimate a
sample size (Wan, 2014). Using an α value of 0.05, with a power of 0.90 and a
calculated effect size of 0.7, we needed 24 patients with hydronephrosis to detect a
2-sided difference in KIM-1 levels before and after the intervention. On the other
hand, if we included 24 patients in each of the groups (hydronephrosis and no
hydronephrosis) we will be able to detect a significant difference in KIM-1 levels
between the two groups, with a power of 0.77, keeping an α value of 0.05.
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A 1:2 ratio of control to study subjects will allow an adequate statistical analysis to
compared the findings all groups of patients. Clinical follow-up included 2
postoperative visit, and we expected a possible 20-25% lost of follow-up, which is
considered acceptable for this type of study (Kristman, 2004). We planned to recruit
30 patients in each of the study groups to complete the calculated sample size.

2.2 Recruitment and follow-up
Exclusion and inclusion criteria were assessed after patients were clinically
evaluated and the surgical treatment was decided during their Urology Clinic visit.
The study was explained to potential candidates, which were invited to participate
in our trial. Patients willing to participate signed appropriate documents according
to out Ethics Board Committee guidelines (Consent Form/Letter of Information)
and were asked to give a mid-stream urine sample (Appendix 3).
Briefly, to be included in the “hydronephrosis group” patients needed to have
unilateral ureteric stricture or unilateral stone disease, both associated with
unilateral hydronephrosis, amenable to treatment by ureteroscopy, percutaneous
nephrolithotomy or pyeloplasty. Patients recruited in the “no hydronephrosis
group” needed to have imaging studies confirming the presence of unilateral stone
disease in the absence of hydronephrosis, and requiring an endourological
procedure as definitive stone treatment.
All patients with active urinary tract infection, evidence of bilateral stone disease,
preoperative presence of ureteric stent, use of indwelling bladder catheter or recent
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history of sepsis were excluded from the study. Appendix 4 describes the specific
details for each inclusion and exclusion group criteria. This study was conducted at
St. Joseph Health Care (SJHC) London, and all recruited patients were required to
have postoperative follow-up in our Urology Clinic.
After patients agreed to participate, demographical, clinical, and radiological
variables were evaluated from patients’ office charts and hospital electronic records
to complete the data collection. It is the standard of practice that patients have a
complete medical assessment the first time they visit the Urology Clinic, and these
variables are evaluated by the treating urologist when discussing with the patient
the best treatment option. The following table describes the variables evaluated at
the first visit.

Table 3. Evaluated baseline characteristics.
Patients then went on to have their surgeries at SJHC, with regular postoperative
follow-up visits in the urologists’ office. We kept track of these visits and according
to our follow-up algorithm urine samples were collected and postoperative
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information was recorded. The following table describes the clinical and
radiological variables evaluated after the surgical management of all patients.

Table 4. Information collected during follow-up visits.
Radiological information was assessed by the treating urologist and was included in
the main database after a careful evaluation of the images in our Centricity, One
View electronic imaging system (GE Healthcare, Barrington, IL, USA). Axial and
coronal reconstruction images from the CT scans were evaluated to determine the
presence and dimensions of the stones. Patients without CT scan, had a KUB and a
renal ultrasound to assess stone characteristics and determine the presence of
hydronephrosis.
The grade of hydronephrosis was determined by evaluating CT scan axial images at
the level of the renal pelvis and calices or transversal renal ultrasound images,
according to the hydronephrosis classification previously discussed (Table 2,
Chapter 1). Incidental findings on imaging studies, such as presence of renal cysts,
tumors, or anatomical anomalies were detailed.
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Serum creatinine is routinely measured in patients before the surgical procedure.
The value was recorded and the eGFR calculated using the CKD-EPI formula
(Levey, 2009). Presence and total leukocyte count per µL of urine and normalized
values of AKI biomarkers (according to urinary creatinine) were recorded.
Healthy subjects from hospital staff were invited to participate as the control group.
A medical interview was completed to evaluate previous medical conditions and to
exclude family and personal history of kidney stones. A bilateral renal ultrasound
was performed by a Urologist, transverse and axial views were evaluated to rule out
the presence of hydronephrosis and kidney stones (Hitachi-Aloka, ProSound SSD
3500, CT, USA; 3.5 Mhz convex transducer). A negative urinalysis was the last
inclusion criteria for controls. Subjects with any abnormality in the renal ultrasound
or an abnormal urinalysis were contacted to have an appointment with a general
practitioner, and were excluded from the analysis.
The recruitment period lasted 10 months, from March 2015 to January 2016. All
follow-up visits were completed by February 2016. All patients and controls were
assessed in the Urology Clinic at St. Joseph Health Care, London, Ontario.

2.3 Urine sample collection
Mid-stream urine samples from all participants were collected in a 100 mL sterile
plastic urine container. A 8 mL conical urinalysis tube was used to collect a portion
of the sample and sent for urinary creatinine measurement and routine urinalysis to
the main laboratory facilities.
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We centrifuged 10-15 mL of urine for 5 minutes at 1000 rpm at room temperature.
The urine supernatant was aliquoted in 1.5 ml Eppendorf tubes and stored at -80C at
our facilities for further AKI markers analysis. All initial samples were labeled with
a unique study number and a research number to cross match and de-identify the
results. Sample handling followed published recommendations to avoid
denaturalization of the markers and were stored within 2 hours of initial collection
(Parikh, 2014).

2.4 Urine sample analysis
Urinary creatinine was measured by enzymatic colorimetric method using the
Roche Modular P Chemistry analyzer, and results were reported as mmol/L
(reference ranges: male, 3.5-25mmol/L; female, 2.6-20mmol/L). A conversion
factor of 88.42 was used to express the creatinine concentration in mg/dl from
µmol/L. Urinalysis was initially performed using dipstick (Multistix SG, Siemens,
Germany) which includes chemical examination for protein, blood, glucose,
ketones, gravity, nitrite, leukocytes and blood. A microscopic analysis was done
only if the dipstick revealed abnormal results, and the total number of red and white
blood cells (cells/high power field) was recorded. The normal range for
microhematuria and leukocyturia in the microscopic examination is < 5 cells/hpf
(Lab Test Information Guideline, SJHC).
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2.5 AKI biomarker levels
AKI marker analysis was comprised in 3 different assays; one each for KIM-1,
Monomeric and Total NGAL. After finishing the recruitment phase the samples
were thawed at room temperature and were analyzed according to the
manufactures specifications of each of the ELISA kits. All urine samples were
diluted to adjust the effective pH for each antibody reaction and the detection limit
of each ELISA experiment.

2.5.1 KIM-1
A commercially available ELISA kit (Human TIM-1/KIM/HAV, R&D Systems,
Minneapolis, MN, USA) was used to determine urinary KIM-1 concentration in all urine
samples. The kit came with a microtiter plate coated with a KIM-1 antibody which binds
to the KIM-1 molecules in the sample, HRP streptavidin which binds to KIM-1 antibody,
TMB substrate which detects HRP streptavidin, KIM-1 standards and buffers. Either
standards or 1:4 dilution of each urine sample followed by biotinylated antibody which
interacts with the KIM-1 antibody followed by Streptavidin/Horseradish peroxidase was
added to each well of the microtiter plate. In between each addition plate was incubated
for 30min at room temperature with mixing at 200rpm. After final 30min TMB substrate
was added. A blue color was generated in the solution and the intensity of blue color was
correlated to the number of KIM-1 molecules in the urine sample. Plate was incubated
exactly 20min at room temperature and the reaction was stopped by changing the pH of
the reaction mixture with stop solution. Absorbance readings of each well at 590nm and
260nm were recorded using the EON BIOTEK plate reader supplied with Gen5 software.
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Background absorbance of each sample was corrected by subtracting the 260nm reading
from that of relevant 590nm one. This whole process was conducted in duplicates.
Standard curve for each plate was created using the absorbance readings of standards and
KIM-1 concentration of each sample (40samples / plate) were calculated.

2.5.2 Total NGAL
The total NGAL ELISA kit (Bioporto Diagnostics, Hellerup, Denmark) was used to
determine the concentration of total NGAL (the three different isoforms of NGAL:
monomeric, homodimeric and MMP-9/NGAL) in urine samples (Pedersen, 2010).
Analysis method was same as KIM-1 but with the plates were coated with antibodies
which were specific for total NGAL and the incubation period after each addition was 1
hour instead of 30mins. Urine samples used in this analysis were diluted in 1:500
according to the manufacturer’s instructions.

2.5.3 Monomeric NGAL
Monomeric NGAL was measured using a commercially available Monomeric
NGAL ELISA kit (Bioporto Diagnostics, Hellerup, Denmark) which contains
Monomeric NGAL specific antibody coated microtiter plate. Analysis procedure
was exactly same as that of total NGAL
Absorbance values that were lower or higher than the detection limit of each
analysis were re-analyzed using either lower or higher sample dilutions. Each of the
obtained values for all three biomarkers was normalized against creatinine levels of
the relevant urine sample by simple division, using the following formula:
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[AKI marker] ng/mL =
[Urine Creatinine] mg/mL

[AKI marker ] ng/mg Creatinine

2.6 Statistical analysis
Our main hypothesis stated that urinary biomarkers would be significantly different
before and after the relief of the obstruction. We have formulated the following
hypothesis for the statistical analysis, allowing an α=0.05:
HO: Median preoperative biomarker levels = Median postoperative biomarker levels
HA: Median preoperative levels ≠ Median postoperative levels

Demographic, clinical and biochemical characteristics were analyzed depending on the
type of variable. Appendix 5 describes the coding of all the analyzed variables during the
recruitment and follow-up of participants. Correlation between hydronephrosis grade and
urine marker levels was evaluated with Spearman coefficient. Continuous variables were
analyzed with Shapiro-Wilk test to determine the normality of the data distribution.
Dichotomous variables were analyzed using Chi-square and Fisher’s exact test and
continuous variables were compared with T-student or Mann-Whitney U test according to
the type of distribution.
The non-parametric Levene’s test was used to evaluate the variances between the the
distribution of the biomarkers levels in the entire cohort. Normalized urine marker levels
were assessed among the different groups using Mann-Whitney U test. Median
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preoperative and postoperative levels were compared with the Wilcoxon signed rank test.
We evaluated the correlation between urinary biomarkers levels and presence of
leukocyturia, stone disease, grade of hydronephrosis and eGFR. De-identified biomarker
results, clinical and radiological data were stored in an electronic database and all
information was analyzed with SPSS v.20 (Armonk, NY, IBM), P-values were derived
from 2-tailed test, and a p<0.05 was considered statistically significant.

2.7 Funding
The study was partially funded by an unrestricted Internal Research Fund award granted
to the investigator team by the Department of Surgery, Schulich School of Medicine &
Dentistry.
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3 Results
We were able to complete the recruitment and follow-up of patients according to the
previously calculated sample size. We decided to initially analyze the urinary
biomarkers’ concentration of only the first and third urine sample, to avoid the possibility
of highly abnormal values related to the presence of leukocytosis in patients with ureteric
stent. These initial results would provide some light about the practicality of evaluating
the second urine sample and save cost of this research project, because high values would
require repeating ELISA analysis, which may increase the initial planned budget.
A total of 66 patients and 12 controls were initially included in our study. Figure 7 is the
flow diagram of the cohort, which shows that 9 patients were initially excluded from
further follow-up due to incomplete baseline information or changes in their management
strategy. A total of 44 patients completed the follow-up; 24 from the hydronephrosis
group and 20 from the no hydronephrosis group. Some patients spontaneously passed the
stone and some others decided to have their clinical follow-up in another city after the
surgical intervention. Only one control subject had an abnormal urinalysis, and was
excluded from the study. Postoperative assessment was conducted with a median of 68
days (IQR 47).
The main hypothesis involved the comparison of AKI markers in patients with
hydronephrosis, and the number of patients recruited fulfilled the sample size calculation.
The statistical analysis for the secondary hypotheses comprised the information from all
patients included in the no hydronephrosis group and the 24 patients who completed the
follow-up in the hydronephrosis group.
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78 Subjects
Total Recruited

66 patients

12 Controls
9 patients

1 Control

Excluded

Excluded

33 patients

24 patients

Hydronephrosis

No Hydronephrosis

Group 1

Group 2

Group 3

9 patients

4 patients

Lost to follow up

Lost to follow up

24 patients

20 patients

11 Controls

Completed Study

Completed Study

Completed Study

Excluded patients: 4 patients did not have follow-up at our center; 3 patients had not finished the follow up at the end of the recruitment
phase and the surgical plan changed in 2 patients after initial enrollment. Excluded controls: one with abnormal urinalysis. All patients
described as “Lost to follow up” were missed in the postoperative visits or had incomplete radiological studies.

Figure 7: Flow chart of patients recruited and patients included in the final analysis.

3.1 Expression of biomarkers in the hydronephrosis group
A total of 24 patients recruited in the hydronephrosis group completed the follow-up.
Stone disease was the most common cause of obstruction in our hydronephrosis cohort
(22/24 patients), while one patient had congenital UPJO obstruction and one had an
acquired ureteric stricture in the mid-ureter. In 63% of the cases the diagnosis was made
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after an episode of acute renal colic, and most of the patients showed moderate
hydronephrosis (grade 2,3) at the time of enrollment. According to the serum creatinine
values, only 4 patients had abnormal preoperative levels, and the median eGFR of the
group was 85 ml/min/1.73m2.
Twenty patients had a ureteroscopy performed, two patients passed the stone while
waiting for the surgical treatment, one had a PCNL to deal with a stone located in the
renal pelvis, and one patient had a robotic pyeloplasty. All procedures were performed
without complications, and one patient with an impacted ureteric stone required
placement of a nephrostomy tube to relieve the obstruction. After completing follow-up,
all patients were stent free and 21 patients did not have hydronephrosis in the
postoperative studies, and 7 showed residual stone fragments. Only three patients had
hydronephrosis at the last study evaluation, two of them had had an impacted ureteric
stone associated with grade 4 hydronephrosis and the patient with UPJO had mild
hydronephrosis during the last follow-up visit.
Demographic characteristics were similar between patients and controls. Table 5 shows
the comparison in the demographic, clinical and radiological characteristics. The
distribution of the absolute and normalized values of Total NGAL, Monomeric NGAL
and KIM-1 were statistically significantly different between hydronephrotic patients and
controls. Figure 8 shows the boxplot graphs of the normalized levels of the three urine
biomarkers in the hydronephrosis and control groups.
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Table 5. Comparison between baseline characteristics of patients with hydronephrosis and
control group
Hydronephrosis
Group
n=
Median (years), IQR
Age
Female/ Male
Gender
BMI Median (kg/m2), IQR
Median (IQR)
CCI
Diabetes/Hypertension
Previous history of stone disease
Diagnosis related to acute renal colic

Imaging study
Cause of obstruction
Site of obstruction

CT scan/Renal
ultrasound
Stone
UPJO/Stricture
Renal pelvis/UPJO
Ureter
Ureteroscopy

Planned procedure

Pyeloplasty
Endopyelothomy

L/R
Side
Median (mm), IQR
Largest diameter of stone
Grade 1 / 2 / 3 / 4
Hydronephrosis
Median (mmol/L)
Preoperative S Cr
Mean (ml/min)
Preop eGFR
Patients with eGFR < 90 ml/min/1.73m2
Patients with eGFR < 60 ml/min/1.73m2
Leukocyturia
Median
ng/dl, (IQR)
ABS KIM-1
Median, (IQR)
NORM KIM-1
Median
ng/dl, (IQR)
ABS Total NGAL
Median, (IQR)
NORM Total NGAL
Median ng/dl, (IQR)
ABS mNGAL
Median, (IQR)
NORM mNGAL

24
58.5, 15
9/15
30.7, 11.6
1 (3)
6/9
13
15

Controls

p value

11
50, 21
4/6
27.9, 9
1(1)

0.09
0.66
0.14
0.16

0
0.376 (0.43)
0.36 (0.8)
8.72 (11.80)
6.32 (8.45)
8.33 (10.60)
5.14 (8.44)

0.045
0.017
0.020
0.030
0.009
0.017
0.016

16/8
22
2
1/1
22
22
1
1
12/12
7 (4)
4 / 12 / 6/ 2
85.5 (32)
78.25 (29)
16
5
7
0.782 (2.57)
1.19 (1.87)
15.84 (28.69)
21.84 (64.46)
12.96 (16.01)
17.54 (25.85)

ABS: absolute; BMI, body mass index; CCI, Charlson Comorbidity Index; mNGAL, Monomeric
NGAL; NORM: normalized values expressed in ng/mg creatinine; S Cr: serum creatinine.
Chisquare test for categorical variables and Student-T test or Mann Whitney-U test for continuous data.

Table 5. Comparison between preoperative characteristics of hydronephrosis group
patients and controls.
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Figure 8. Boxplot graph showing the distribution of normalized values of
biomarkers in patients with hydronephrosis and controls.
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Except for three patients, all others in the hydronephrosis group showed a decreased
urinary level of KIM-1 in the postoperative visit compared to the preoperative
concentration. One of those three patients had pre-existing CKD and residual
hydronephrosis, the other two only showed leukocyturia and residual stone disease.
Figure 9 is a waterfall plot that shows the change in the postoperative levels of KIM-1
after surgical management of the 24 patients in the hydronephrosis group.
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Figure 9. Waterfall plot showing the change in KIM-1 levels before and after
treatment in all patients from the Hydronephrosis Group.
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Based on previous research, we designed this study to evaluate if the normalized urinary
levels of the KIM-1 and Monomeric NGAL were different after treatment and relief of
the unilateral obstruction (alternative hypothesis -HA-), the null hypothesis (H0) stated
that the median levels of the biomarkers were similar before and after treatment.
Wilcoxon Signed Rank test showed no significant differences in the Total and
Monomeric NGAL levels, while on the contrary KIM-1 was statistically significantly
lower after treatment (Table 6, Figure 10). Regarding Total and Monomeric NGAL the
H0 was accepted, although it has to be rejected for KIM-1, accepting the fact that KIM-1
levels significantly changed after relieving the unilateral obstruction.

Table 6. Comparison of preoperative and postoperative urinary biomarkers'
concentration.
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Figure 10. Boxplot graph showing the distribution of normalized values of
biomarkers in patients with hydronephrosis before and after treatment

62

Considering that 3 patients had residual hydronephrosis after the treatment and 7 patients
had residual stone fragments, we performed a post hoc analysis excluding these
postoperative samples. Results were similar, showing only significant differences in
KIM-1 levels, after comparing 24 vs 21 patients (residual hydronephrosis) and 24 vs 15
(residual hydronephrosis and/or stones) (Table 7).

Table 7. Post hoc analysis including patients without residual hydronephrosis and
residual stone after treatment.

After resolution of the hydronephrosis, KIM-1 concentration decreased to levels that
were statistically similar to of the control group (0.76 vs 0.36 ng/ml creatinine, p=0.36).

3.2 Factors associated with biomarkers expression
The results of the following sections are based on the inclusion of the baseline
characteristics of all recruited patients with complete information and the urinary
biomarkers’ concentrations of the first collected urine samples (preoperative). Some
statistical analyses also integrated the results obtained from the control group, in this
case, a note is made.
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3.2.1 Comparison of biomarker levels in patients with and
without hydronephrosis
Demographic, radiological and biochemical characteristics of the two groups of patients
are shown in Table 8. Both groups were comparable in terms of age, gender,
comorbidities, and previous history of stone disease. Besides the obvious difference in
the hydronephrosis status, we also found significant differences in the number of patients
diagnosed after an episode of renal colic, the size of the treated stone and the
preoperative serum creatinine (p<0.05). Despite the disparities in the preoperative
creatinine levels, the calculated eGFR was similar between both groups. The number of
patients with CKD stage ≥ 3 was significantly higher in the hydronephrosis group and no
differences were found in the presence of leukocyturia.
The distribution of the preoperative levels of the biomarkers is also shown in Table 8.
Interestingly, patients with hydronephrosis had significantly higher levels of absolute and
normalized KIM-1 compared to those patients without hydronephrosis. (p=0.035,
p=0.006). Monomeric and Total NGAL failed to show a significant difference between
the group of patients with hydronephrosis and those without it. After comparing the
postoperative levels in the two groups, we did not find any significant difference in the
median values of KIM-1 (p=0.81), Total NGAL (p=0.89) or Monomeric NGAL
(p=0.37).
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Table 8. Comparison between baseline characteristics of hydronephrosis and no
hydronephrosis groups.

n=
Age
Gender
BMI
CCI

Median (years), IQR
Female/ Male
Median (kg/m2), IQR
Median (IQR)

Diabetes
Hypertension
Previous history of stone disease
Side
L/R
Acute episode
Largest diameter (axial)
Hydronephrosis

Median (mm)
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4
Median (mmol/L)

Preoperative S Cr
Preoperative eGFR
Mean (ml/min)
ml/min/1.73m2
Patients with eGFR < 90 ml/min/1.73m2
Patients with eGFR < 60 ml/min/1.73m2
Leukocyturia in
Median, IQR
NORM KIM-1
Median, IQR
NORM Total NGAL
Median, IQR
NORM mNGAL
Additional findings
Cyst
Renal mass

Patients with
hydronephrosis

Patients without
hydronephrosis

24
58.5, 15
9/15
30.7, 11.6
1 (3)
6
9
10
16/17
15

24
57, 19
12/12
29.5, 6.55
2
3
11
9
15/10
4

0.74
0.56
0.65
0.61
0.46
0.77
1
0.38
0.0001

7

8.5

0.021

0
4
7
11
2
85

24
0
0
0
0
75

0.0001

76.9

84.5

0.21

16
7
7
1.19 (1.87)
21.84 (64.46)
17.54 (25.85)
2
2

13
0
6
0.64 (0.88)
25.26 (40.7)
22.76 (25.14)
3
1

0.17
0.016
1
0.006
0.88
0.35

p value*

0.043

1

*categorical variables were compared using Chi-square test; continuous variables were compared
with Student's T-test or Mann-Whitney U test. mNGAL: Monomeric NGAL; NORM: normalized
values expressed in ng/mg creatinine; S Cr: serum creatinine.

Table 8. Comparison between hydronephrosis and no hydronephrosis groups.
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3.2.2 Correlations between biomakers and grade of
hydronephrosis
For the evaluation of these possible correlations, we included the preoperative
information of all patients and controls. We used Spearman’s test to correlate the urinary
levels of the normalized biomarkers and the grade of hydronephrosis. KIM-1 was the
only biomarker showing a significant correlation with the grade of hydronephrosis, and a
moderate correlation (rs=0.39, p=0.002). Total and Monomeric NGAL did not correlate
with the grade of hydronephrosis.

3.2.3 Correlations between biomarkers and renal function
Serum creatinine levels were available for all recruited patients. Biomarkers’ levels from
preoperative urine samples were used to evaluate a possible correlation with the renal
function measured by serum creatinine, estimated GFR, and by CKD stage according to
the Kidney Disease Improving Global Outcomes classification (KDIGO). We did not
find any significant correlation for any biomarker (Table 9). Our hypothesis that KIM-1
and Monomeric NGAL would correlate with the overall renal function was not proven.
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Table 9. Correlation between normalized biomarkers’ values and different ways to
assess renal function.

3.2.4 Other correlation analyses with biomarker levels
We explored the association of preoperative continuous variables with the concentrations
of the biomarkers. The preoperative information from all patients (48) was used. The
normalized values of all three biomarkers positively correlated with the Charlson
Comorbidity Index, but after adjusting for the age, these correlations were no longer
significant (p>0.05). No correlations were found between the mean largest diameter of
the stone and the level of any biomarker.
After analyzing the preoperative urine samples, the grade of leukocyturia showed a
moderate correlation with the normalized levels of Total and Monomeric NGAL
(rs=0.43, p=0.007, rs=0.45, p=0.001) respectively, similar correlations were found
evaluating the postoperative urine sample, and these remain significant after adjusting
for age and CCI. Patients showing leukocyturia in the preoperative urine sample had
significantly higher levels of Total and Monomeric NGAL (p=0.016, p=0.010) than
those patients without leukocyturia, independently of the group they belonged to. None
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of those patients had significant findings in the urinalyses suggesting a urinary tract
infection, and all postoperative urine samples were from stent free patients. KIM-1 was
not associated with the presence of leukocyturia. KIM-1 levels were similar between
patients with and without preoperative leukocyturia (p=0.01).
To evaluate any possible correlation between the three urinary biomarkers, we analyzed
the preoperative urine samples of all patients and controls. We found significant
correlations between all the markers, from weak to strong, being higher between Total
NGAL and Monomeric NGAL as it would be expected (Table 10). Interestingly, the
strength of the correlations was different among patients without hydronephrosis
compared to the coefficients of patients with obstruction (Table 11).

Table 10. Correlation coefficients between normalized biomarker levels in the first
urine sample.

68

Table 11. Correlation coefficients between preoperative biomarkers in both groups.

The initial sample size calculation was formulated in line with previously reported KIM1 values. The inclusion of Monomeric NGAL analysis in our study, made it the first
clinical trial evaluating this marker which previous reports suggesting it was more
specific for AKI. In view of our results, we decided not to analyze the second urine
sample of the patients, because results from Total and Monomeric NGAL would be
affected by leukocyturia, which is expected with the presence of a ureteric stent.

3.3 Biomarker expression in the no hydronephrosis group
Demographic characteristics between the no hydronephrosis group and controls showed
no differences, except for the presence of comorbidities measured by the Charlson
Comorbidity Index (CCI): patients had a median CCI of 2, while controls had a median
of 1. After comparing the normalized values of the biomarkers we found that Total and
Monomeric NGAL were significantly different both in the preoperative and
postoperative urine samples. KIM-1 measurements did not significantly differ at any
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point of the follow-up between controls and patients in the no hydronephrosis group
(Table 12).
We also compared the preoperative and postoperative levels and we found that values
were not statistically significantly different despite the intervention for the stone disease.
(KIM-1 p=0.30, Total NGAL p=0.33, Monomeric NGAL p=0.25). Figure 11 is a beforeafter graph of the KIM-1 in this group which shows comparable results despite the
treatment.

No Hydronephrosis Group
4.50

KIM-1ng/ml creatinine

4.00
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
Preoperative

Postoperative

Figure 11. Before-after graph of KIM-1 levels in no hydronephrosis group.

70

Table 12. Biomarkers’ concentration between the no hydronephrosis group and
controls.

3.4 KIM-1 as a diagnostic test for hydronephrosis
Using ROC Curve analysis with the preoperative urine sample of all patients, we were
able to calculate the best cut-off point for normalized KIM-1 to predict the presence of
hydronephrosis either in the preoperative CT scan or renal ultrasound. The area under the
curve (AUC) was 0.73 (95% CI 0.58-0.87, p=0.006), and a KIM-1 value of 0.735 ng/mg
creatinine was the balance point to achieve the highest sensitivity (75%) and specificity
(67%) (Figure 12). The Positive Predictive Value (PPV) is 59% and the Negative
Predictive Value (NPV) 77%.
None of the other analyzed biomarkers showed a significant AUC to detect
hydronephrosis. If we use the preoperative and postoperative urine samples with their
imaging studies as independent events, the AUC to detect hydronephrosis for KIM-1 was
0.69 (95% CI 0.58 - 0.81, p=0.003).
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Figure 12. ROC curve for hydronephrosis detection using KIM-1.
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4 Discussion and Conclusions
We were able to complete the recruitment and follow-up of patients according to the
previously calculated sample size. After these initial results we decided to analyze only
the first and third urine sample to avoid the possibility of highly skewed values related to
the presence of a ureteric stent in the second sample. We will see that because KIM-1
was not affected by the presence of leukocyturia, further analysis of KIM-1
concentration in the second urine sample will be performed. The sample size calculation
was based on the previously reported urinary levels of KIM-1, but we also had planned
to explore the expression of Total and Monomeric NGAL. In order to correct for
individual urinary protein production and hydration status, the normalized biomarkers
levels were used to perform the statistical analysis, as all the recent literature
recommends (Hsu, 2015). The urinary levels of the three biomarkers in patients with
hydronephrosis were statistical significantly different compared to the control group.
This information has been proven by several urological studies, demonstrating that
biomarkers are able to discriminate between healthy subjects and patients with the
specific renal disease, such as obstruction or infection (Cost, 2013; Xie, 2014; Yilmaz,
2009).
We believe our results provide a comprehensive overview of the expression of the
studied biomarkers in these groups of urological patients. According to our design, the
findings are statistically strong enough to prove differences and similarities in the
expression of KIM-1 in the three studied groups. The information was prospectively
collected, and the statistical tests should be considered adequate for non-normally
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distributed data. Specific assumptions for each test were taken into consideration to
properly analyze all the variables in the different hypotheses involving the three
biomarkers. We should be cautious in the interpretation of the results regarding the
expression of Monomeric NGAL however, because of the exploratory nature of the study
in this regard. We acknowledge that the negative results about Total and Monomeric
NGAL could result from a small sample size, but the correlation noted with the levels of
leukocyturia may affect their usefulness in urological patients. This observation should
be taken into account if further studies are planned to assess these particular biomarkers.

4.1 Biomarkers expression in hydronephrosis group
Patients with hydronephrosis had significantly higher levels of urinary KIM-1 at baseline
compared to at the end of the follow-up period, after the obstruction was relieved.
Likewise, this group of patients demonstrated an increased level of urinary KIM-1
compared to both patients with stone disease without obstruction and healthy control
subjects. These results may corroborate the fact that hydronephrosis due to obstruction
causes kidney injury measured by the increased expression of the biomarker. It could be
designated as subclinical, because serum creatinine was within the normal limits, but
slightly higher in the obstructed patients, compared to the other studied groups. If
treatment decisions were to be based on serum creatinine levels, treatment might be
delayed especially in patients with unilateral obstruction and normal contralateral kidney
function.
From our perspective, the most important finding is the fact that KIM-1 elevation
appears to be related to the presence of obstruction. As a reflection of the presence of
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AKI injury, KIM-1 could potentially be used as a hydronephrosis biomarker in several
clinical situations. More large-scale studies are needed to validate the feasibility of its
widespread use as an accurate marker of obstruction.
Most of the longitudinal studies about biomarkers expression in patients with
hydronephrosis have evaluated pediatric patients. Karakus studied 4 urinary biomarkers,
including Total NGAL and KIM-1, in patients with obstructive antenatal hydronephrosis.
He found that all biomarkers were higher compared to the control group, and NGAL and
KIM-1 decreased to the levels showed by control group 6 months after the surgery.
Interestingly, urinary KIM-1 concentration of the control group was very similar to what
Wasilewska and collegues found in another set of pediatric patients with UPJO, and to
our findings (0.60 vs 0.58 vs 0.36 ng/mg creatinine) (Karakus, 2015; Wasilewska, 2010).
We found that KIM-1 decreased after relieving the obstruction, but not as low as the
control group (0.75 vs 0.36 ng/ml), and this could be explained by the time lapse
between surgery and the collection of the second postoperative urine sample. In our case
it was only 2 months, compared to 6 in Karakus’ study. The other reason might be the
fact that patients in both studied groups already had some sort of CKD (29 out of 48
patients had an eGFR < 90 ml/min), which could be associated with higher baseline
levels of KIM-1. A recently published case-control study about urinary biomarkers of
and risk for ESRD (End-Stage Renal Disease), revealed that patients with ESRD had
increased levels of urinary biomarkers, specifically, patients who developed ESRD had a
mean baseline KIM-1 level of 914 pg/mg creatinine (0.914 ng/mg creatinine) compared
to controls who showed a median concentration of 665 pg/mg creatinine (0.665 ng/mg
creatinine) (Foster MC, 2016).
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Another objective of this study was to also evaluate a group of patients with obstruction
who had undergone diuretic renography. These are usually patients with congenital
UPJO who required this investigation for diagnosis. We wanted to explore the expression
of these markers before and after treatment and compare it to the actual “gold standard”
and the radiological appearance of hydronephrosis. Unfortunately, the actual recruitment
of UPJO patients was quite low; only 4 patients were initially recruited and one finished
the study. This patient showed a decreased urinary concentration of KIM-1 in the
postoperative urine sample, despite showing residual hydronephrosis in the imaging
studies. No definitive conclusion can be made, but the recruitment of patients with UPJO
will continue in order to explore the relationship between urinary marker expression and
obstruction evaluation by renography. Although studies in the pediatric population
suggested the potential usefulness of these biomarkers, results cannot be extrapolated to
adult patients because most of the pediatric patients with UPJO obstruction have
antenatal hydronephrosis which may affect the development of the renal parenchyma and
the subsequent expression of biomarkers (Karakus, 2016; Madsen, 2013).
Urbschat and collegues in a cross-sectional study evaluated the expression of serum and
urinary NGAL and KIM-1 in patients with “acute obstructive nephropathy”. Their main
results were different from our findings: KIM-1 was similar between controls and
patients, and serum and urinary NGAL was statistically significantly different between
both groups; they concluded that NGAL could be a potential marker of postrenal AKI.
An important drawback of this study is the fact that all included patients with acute renal
colic were considered to have postrenal AKI, despite the presence of hydronephrosis or
the serum creatinine level. Additionally, patients with renal colic without hydronephrosis
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were included in the studied group. The authors concluded that NGAL and a “negative
urinary KIM-1” may facilitate the diagnosis of postrenal AKI (Urbschat, 2014). On the
contrary, Xie et al, found a correlation between the preoperative and early postoperative
urinary levels of KIM-1 in patients with obstructive nephropathy with the recovery of
renal function 1 year after obstruction management. This conclusion raises the possibility
of using KIM-1 not only as a diagnostic test, but also as an objective prognostic tool in
patients with obstructive nephropathy (Xie, 2014). Sabbisetti also found the prognostic
value of serum KIM-1 to predict the loss of GFR in diabetic patients with CKD
(Sabbisetti, 2014).
Whether KIM-1 has a protective role in cases of acute injury, or promotes a fibrotic
process by its chronic expression, remains to be determined (Humphreys, 2013; Yang,
2015). Further details about its expression in the acute and chronic setting must be
addressed in future basic and clinical research.
The urinary levels of Total and Monomeric NGAL were similar in patients with
hydronephrosis before and after the relief of the obstruction, corroborating the absence of
hydronephrosis with imaging studies in 21 of the 24 patients. All postoperative analyzed
urine samples came from stent free patients. We determined if the presence of residual
hydronephrosis affected the NGAL levels using a post hoc analysis. By excluding cases
with residual hydronephrosis or stone fragments after the procedure, we did not find
significant differences in Total and Monomeric NGAL concentrations.
We believe that by including patients without urgent indications for active management,
we automatically excluded patients with systemic inflammatory response symptoms
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(SIRS) from our trial. This allowed a more objective measurement of the impact of
hydronephrosis in the expression of Total and Monomeric NGAL by removing
inflammation as a potential cause from NGAL release.
Despite many research studies concluding that urinary and serum NGAL are reliable
markers of AKI in other populations, Martensson and Bellomo discussed some reasons
that may explain the differences in the diagnostic performance of NGAL for AKI in the
published literature: 1) the use of creatinine as a “gold standard” to compare the global
renal function may affect the sensitivity of the biomarker in “serum creatinine falsenegative AKI”, 2) chronic comorbidities that may affect the baseline expression of
NGAL (i.e. CKD) 3) variations in the time lapse of biomarker measurement, and 4) the
absence of specific essays to differentiate between the different NGAL isoforms
(Martensson, 2014). In our study, we tried to account for one of those factors by
measuring the Monomeric NGAL isoform.
We are the first group to explore the urinary expression of Monomeric NGAL using a
new ELISA kit claiming to have < 1% of cross reaction with Homodimeric NGAL. We
hypothesized that by measuring the monomeric isoform, which is more specific for
tubular epithelial cells, the diagnostic performance for kidney injury would increase
(Bangert, 2012; Cai, 2010; Nickolas, 2012). Total NGAL and Monomeric NGAL
showed similar expression in the studied groups, and no associations were related to the
presence of hydronephrosis. Furthermore, the median values in the postoperative
evaluation were higher than the baseline levels, but differences were not significantly
different.

78

After analyzing our results, and comparing them with the previous literature, we believe
that urinary KIM-1 has shown a promising future as an AKI marker in urological
patients. If future studies corroborate our findings, and they find a correlation between
the biomarker levels and the baseline renal function, we may have an opportunity to
evaluate the prognostic significance of a urinary marker in urological patients.
We have proven that despite the presence of normal median values of serum creatinine,
patients with unilateral ureteral obstruction have increased levels of urinary KIM-1
which has been recognized as an accurate marker of early kidney injury. Given that
serum creatinine has failed to accurately stratify our patients with UTO because it cannot
detect “subclinical injury” and a substantial decrease in the glomerular filtration is
needed to affect the serum levels of creatinine, KIM-1 emerges as a potential biomarker
in this set of patients.
Further research should be conducted to elucidate the physiology behind the expression
of KIM-1 during acute and chronic renal injury. In addition, further work is required to
assess the effect of unilateral obstruction in the biomarkers levels in the affected unit
compared to the bladder.

4.2 Biomarkers expression in studied groups:
hydronephrosis vs no hydronephrosis
Our results suggest that urinary KIM-1 has the potential to become a useful marker for
subclinical AKI associated with the presence of unilateral urinary obstruction. The
design of the study allowed the evaluation of KIM-1 expression in a longitudinal (before
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and after treatment) and cross-sectional fashion: KIM-1 was significantly higher in
patients with hydronephrosis compared to patients with stone disease and no
hydronephrosis, with similar demographic and medical characteristics. While we found
significant differences in the serum creatinine levels, the median eGFR between the two
groups was similar, and the number of patients with eGFR < 90 ml/min was comparable,
although the median serum creatinine value of both groups was within the normal limits.
Several important findings need to be underlined to better understand our results:
1)KIM-1 levels were higher in patients with hydronephrosis, 2) the median postoperative
level of KIM-1 in the hydronephrosis group after treatment was similar to what patients
without hydronephrosis showed after surgery (0.75 ng/ml creatinine), 3) median KIM-1
level of the control group was significantly different only in the hydronephrosis group,
and 4) despite the significant differences in Total and Monomeric NGAL levels between
the hydronephrosis and control groups, the expression of these two markers was similar
among the two groups of patients before and after relieving obstruction.
Our study is the first to analyze the impact of biomarkers’ expression before and after
treatment in such detail. As briefly mentioned, there have been some studies that
evaluated KIM-1 expression in hydronephrotic adult patients: Ursbchat et al did not find
differences in the expression of urinary KIM-1, but they compared patients with acute
renal colic without differentiating the presence or absence of hydronephrosis. Their
results regarding NGAL expression could be affected also by the presence of SIRS
commonly associated with renal colic. We mentioned that Xie and colleagues found that
KIM-1 was a good predictor of AKI and a prognostic tool to determine the recoverability
of renal function after an episode of obstructive nephropathy. These results should be
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cautiously evaluated because the mean eGFR of the included patients was 11.5
mL/min/1.73m2, and those with better function recovery had a mean eGFR 53.5
mL/min/1.73m2 showing a large proportion of patients with late stages of CKD, and the
results might not be reproduced in patients with normal eGRF (Xie, 2014; Xue, 2014).
We also compared the levels of the three biomarkers in patients without hydronephrosis
to the control group. Table 12 showed that both Total and Monomeric NGAL were
different between preoperative and postoperative samples in the no hydronephrosis
group in comparison with the controls. If these markers were good parameters of AKI in
our population we would expect to be similar in the absence of hydronephrosis. Only
KIM-1 was comparable in those groups, irrespectively of the presence of urolithiasis,
suggesting that urinary KIM-1 is only affected by the presence of hydronephrosis.

4.3 KIM-1 correlated with the grade of hydronephrosis
In our study, KIM-1 was the only biomarker associated with the grade of
hydronephrosis. After evaluating the performance of Total and Monomeric NGAL in
both groups of patients, the correlation analysis confirms that these urinary biomarkers
are not accurate enough to detect hydronephrosis in patients with co-existing conditions
associated with urinary tract inflammation. In fact, the difference in the preoperative and
postoperative levels was not statistically significant, although numerically both
biomarkers were elevated. This previous finding was not expected, based on the
published information as we hypothesized that at least Monomeric NGAL would have
better correlation than Total NGAL with the occurrence of hydronephrosis. The grade of
hydronephrosis positively correlated with the expression of KIM-1. Despite the fact that

81

the 24 patients with hydronephrosis were divided by 4 grades, which may have
decreased the chances of finding an association, we found a moderate correlation
between both variables. We envision a large scale multicentric study which may be able
to corroborate our findings, especially about the the impact of baseline renal function in
the expression of KIM-1. Such a study may evaluate the likelihood of using KIM-1 as a
potential tool to stratify the management of patients with hydronephrosis according to
the baseline renal function.
Postoperative KIM-1 levels in patients with hydronephrosis were lower than before
obstruction management, and almost all patients without hydronephrosis in the follow-up
studies had decreased levels. While measuring the concentration of biomarkers in voided
urine specimens may reflect the status of both renal units, and possibly “dilute” the
biomarkers concentration of the affected unit, we aimed to assess an easy to perform and
non-invasive test. The idea of evaluating the unilateral expression of the biomarkers
would require an invasive procedure such as percutaneous nephrostomy insertion or
retrograde catheter placement to collect urine from the affected unit. A ROC analysis
showed that KIM-1 had a sensitivity of 75% and specificity of 67% to detect
hydronephrosis. We believe this outcome deserves further evaluation in a large
prospective cohort study to increase the number of patients with the different grades of
hydronephrosis. The small number of patients in each of the hydronephrosis grade
categories precluded a more specific analysis by each individual category.

4.4 Biomakers and overall renal function
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Several studies have shown a correlation between the AKI markers expression and renal
function. Malyszko and collegues evaluated KIM-1 and NGAL in blood of patients after
successful kidney transplantation, and the later had a strong correlation with serum
creatinine levels (Malyszko, 2010). In our previous study, we found a higher level of
urinary KIM-1 in patients with CKD compared to those with normal eGFR (Fahmy,
2013). Based on this and other findings previously discussed, we expect a certain grade
of correlation between renal function and the biomarkers’ baseline levels. None of the
three evaluated biomarkers showed a significant correlation with the renal function
measured by serum creatinine or the calculated eGFR. Furthermore, the CKD categories
did not affect the baseline levels of any marker.
One important fact that should be addressed, is that serum creatinine might not be the
best reference standard, despite being the most commonly used test to measure global
kidney function (Siew, 2011). The time between the acute episode of obstruction and the
inclusion of the patients varied in this study. All patients were recruited in the Urology
Clinic without needing an urgent intervention, which may affect the acute expression of
the markers. This needs further evaluation, because the increment of creatinine levels
depends on the individual renal reserve and the length of time between the renal insult
and the evaluation.
McIlroy prospectively evaluated the relationship between urinary NGAL and baseline
renal function in patients undergoing cardiac surgery. They found a positive relationship
between these two variables only in patients with an eGFR > 60 ml/min (McIlroy, 2009).
This study included more than 400 patients and showed no differences in the
perioperative NGAL levels despite the development of AKI in patients with CKD stage 4
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and 5, which underlies the importance of baseline renal function on the biomarkers
expression. Besides the fact that NGAL might be affected by the presence of
leukocyturia, and these patients usually have a bladder catheter, they showed an
association only in patients with normal baseline function. The small sample size of our
study precluded the possibility of finding a positive relationship between the renal
function and the eGFR.
Although it was found that KIM-1 levels decreased after the treatment of the
hydronephrosis, and that the perioperative values of KIM-1 in patients without
hydronephrotic were similar to the control group, they were numerically higher. This
finding might be explained by the fact that patients had some degree of CKD compared
to the controls, assuming that subjects included in the control group had normal renal
function. One limitation of this study is the fact that serum creatinine was not measured
in the control group, and despite enrolling patients without significant comorbidities and
assuming a normal renal function, the actual serum creatinine and eGFR were not
available for analysis.

4.5 Other factors related to biomarkers’ expression
Initially, we found a moderate correlation analysis between age, Charlson Comorbidity
Index, eGFR and the biomarkers’ expression. After adjusting for other clinical variables
however, this correlation was not found to be significant. No other demographic or
medical variables evaluated were correlated with the biomarkers’ levels.
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Ours is not the first study showing an association between leukocyturia and the
expression of any of the biomarkers. As we previously discussed, a case-control study
found that urinary levels of NGAL were higher in patients with UTI than in controls; the
same group in another study found a correlation between NGAL and the grade of
leukocyturia (Urbschat, 2014). Decavele et al studied the urinary expression of NGAL
and the presence of white cells in urine and concluded that high count of leukocytes
contributes to the expression of urinary NGAL, and proposed a correction factor to
increase the accuracy of the test (Decavele, 2011). The authors used a different assay to
analyze the levels of NGAL precluding the use of their formula in our study,
nevertheless our results showed a significant correlation between both Total and
Monomeric NGAL and the presence of leukocyturia.
We recognize that leukocyturia is a very common finding in urological conditions, and
despite the use of a more specific isoform to detect subclinical AKI such as Monomeric
NGAL, the nature and origin of the NGAL molecule may preclude its use in this set of
patients. Leukocyturia may be caused by the presence of residual stone disease, urinary
infection, or by the presence of indwelling catheters or ureteric stents.
KIM-1 seems to be expressed in the voided urine specimen without any significant
correlation with the presence of leukocyturia. In a previous study, assessing the impact of
endourological management in the expression of KIM-1, we found that ureteroscopy did
not significantly affect the urinary levels of KIM-1 (Nader, 2013). This is of particular
importance because in this cohort study we analyzed postoperative samples at a median
follow-up of two months after the surgical procedure. Both studies support the fact that
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inflammatory conditions of the urinary tract, specifically stone disease or endourological
manipulations, do not affect the levels of KIM-1.
Our study answered some questions regarding the expression of these markers in
urological patients. Most of the large scale studies evaluating AKI biomarkers in the
emergency department excluded patients with urological conditions. We have found that
KIM-1 appears to be unaffected by the presence of kidney stones, and we corroborated
the fact that leukocyturia could potentially affect the urinary levels of Total and
Monomeric NGAL. Researchers may consider these facts when designing future studies
about the impact of different renal conditions on the expression of AKI biomarkers.

4.6 Limitations of the study
Despite the prospective design of this cohort study and the meticulous criteria for patient
inclusion and exclusion, our study is not without limitations. Due to the fact than we did
not want to interfere with the standard of treatment, some patients had to be excluded
from the final analysis. After the enrollment in the study, some patients had their followup in another city or did not return for clinical and urinary biomarker evaluation due to
missing their appointments. Furthermore, due to the nature of this observational study,
the follow-up was not completely standardized and in some cases the clinical evolution
of the patient changed the usual postoperative evaluation and the subsequent exclusion of
the patients from the final analysis. Despite this, 48 out of 66 patients were included in
the final analysis which allowed us to perform the planned analysis. It is accepted that
cohort studies have the potential to experience information bias, meaning that the
exclusion of subjects lost to follow-up may affect the results. For these reasons, and
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specially after this type of exploratory study, our results need to be replicated in a larger
group.
We assumed that the renal function of the healthy subjects was normal, and this may be a
limitation while trying to correlate the expression of the biomarkers with the eGFR,
because these subjects were not included in that analysis. In order to facilitate the
recruitment of controls, we decided not to evaluate this parameter. Along with this
limitation, we did not measure the serum creatinine at the follow-up visits in the included
patients because it is usually not within the standard of care. However, it may have
helped determine if the changes in the evaluated biomarkers had a correlation with the
evolution of this parameter after the resolution of the obstructive process.
Another limitation is the fact that not all preoperative imaging studies were performed
the same day patients gave the urine sample for biomarker analysis. The evaluated
preoperative imaging study might not have reflected the dynamic evolution of the urinary
tract obstruction. As we previously mentioned, this was due to the observational design
of the study. All postoperative urine samples however, were collected the same day the
imaging study was performed, reassuring the relationship between the absence of
hydronephrosis and the decreased levels of KIM-1.
The fact of including patients with different causes of hydronephrosis in group 1 (stone
disease, UPJO, ureteric stricture) could be interpreted as a limitation, because the
outcomes from a renal function perspective could be different. Nevertheless, the design
was made to evaluate the impact of hydronephrosis in the levels of the biomarkers,
independently of the cause. For this reason we determine that the exposure variable
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would be the obstruction detected by imaging studies, and the main objective the urinary
levels of the three biomarkers before and after the surgical management.
We acknowledge that hydronephrosis is not a synonym of obstruction, and there are
some conditions, as those discussed in Chapter 1, that are not associated with urinary
tract obstruction. Nevertheless, the standard clinical practice in urology assumes that in
the presence of a stone the associated hydronephrosis reflects an obstructive process. It is
not clinically useful or ethical to perform a renogram to determine if these patients are
truly obstructed in order to define the most appropriate management. Equivocal cases,
where hydronephrosis is not always a sign of obstruction, such as in patients with UPJO,
require a renogram with diuretic for correct diagnosis (Ozayar, 2015). We planned to
include these patients, however, the number of adult patients presenting UPJO was low,
and only one patient completed the study.

4.7 Future directions
These results have identified an association with hydronephrosis and the urinary
expression of KIM-1. While Total and Monomeric NGAL did not show a correlation
with the presence of hydronephrosis, our results support a possible relationship with
leukocyturia, hindering its use in this population.
The recruitment of patients with UPJO will continue in order to evaluate the correlation
of these biomarkers with the renogram results, a study that is considered the “gold
standard” for the diagnosis of urinary tract obstruction. As we previously discussed,
some studies have evaluated the expression of these biomarkers in the pediatric
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population, but there are no published studies with adult patients. We believe our results
should be further evaluated in a large multicentric scale study including clinical and
biomarker assessment in the acute renal colic event. KIM-1 analysis will be performed
for the second urinary sample, and it will help to determine if the presence of double J
stent affects the urinary concentration. As we previously mentioned, the analysis of the
second urine sample for Total and Monomeric NGAL will not be performed in order to
save economical resources.
Although, several questions regarding the actual function and significance of these
molecules that are expressed in early renal injury remain unanswered, this study adds
important information to the existing literature and raises the interest of finding a reliable
marker of obstruction, even in cases with subclinical AKI. On the other hand, KIM-1
should be evaluated in future studies as a potential point-of-care test to rule out the
presence of obstruction, where normal values may predict the absence of AKI and may
save further imaging in patients with urinary tract obstruction.
Future research is needed to corroborate if KIM-1 would be a sensitive and specific
urinary test to detect AKI in urological patients. The promising implications in clinical
practice include the possibility of prioritizing non-urgent management in patients with
urinary tract obstruction, by having an objective measurement to detect AKI, but also the
fact that KIM-1 seems to be not affected by inflammatory conditions may allow the
inclusion of this set of patients in further research about these biomarkers.
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Appendix 3 – Consent and Letter of Information

Biomarkers of Kidney Injury in a Urological Population
Letter of Information
Principal Investigator:
Co‐Investigators:

Dr. Hassan Razvi
Dr. Stephen Pautler & Dr. John Denstedt

INTRODUCTION
You have been asked to voluntarily participate in this research study because you have been scheduled for
treatment/surgery for your kidney stone(s).
PURPOSE
The purpose of this study is to analyse your urine for the presence of some proteins that your kidney may
release due to stone disease and/or an obstructed kidney. These protein biomarkers may be helpful in the
future diagnosis and management of patients with these urological conditions.
STUDY SELECTION
It is expected that 150 patients, both men and women, will be enrolled, at St. Joseph’s Hospital, St. Joseph’s
Health Care London.
PROCEDURES
If you agree to participate, information about you (age and gender) and about your medical and urological
history as well as information about your current urinary condition and treatment will be collected. You will
be asked to provide a voided urine sample before your surgery and again at each of your follow‐up
appointments at 3 to 6 weeks and again at 3 to 6 months, here at St. Joseph’s Hospital.
A portion of your each of your urine samples will be sent to the hospital laboratory for routine
microscopy/chemistry and to test the level of creatinine (how well your kidneys filter waste). The remainder
of each sample will be shipped to the Laboratory at Harvard University for biomarker analysis. The data
from all participants will be compiled and the analysis will be done here at St. Joseph’s Hospital.
RISKS
The specific risks associated with your surgical procedure will be explained to you by your urologist. There
are no known additional risks associated with your participation in this study.
BENEFITS
You will not receive any benefit from participating in this study. However, your participation in this research
study may help future patients.
PARTICIPATION
Participation in this study is voluntary. You may refuse to participate, refuse to answer any question or
withdraw from the study at any time with no effect on your future care. To protect the integrity of the
study, you will not be able to withdraw your data from the study after your urine samples have been
Biomarkers of Kidney Injury in a Urological Population
Version dated 9 December2014
Page 1 of 3

Patient Initials:_______________________
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collected and sent for analysis. You may also be withdrawn without your permission, if, in the opinion of the
investigators, further participation would not be in your best interest.
You do not waive any legal right by signing the consent form. Every precaution will be taken to prevent any
injury to you during the study. However, if an injury does occur, you will obtain medical care in the same
way that you normally would obtain your medical care.
ALTERNATIVES
As an alternative to participation in this study, you may choose not to participate and no urine will be
collected for the study.
COMPENSATION
You will not be paid for your time for taking part in this study.
CONFIDENTIALITY
All information obtained during the course of this study is strictly confidential. You have a right to privacy
and as permitted by applicable law, all reasonable measures will be taken to protect the confidentiality of
your records. Your urine samples will be sent to the laboratory at Harvard University and will be identified
only with a unique study number. Information resulting from this study and from your medical record may
be used for research purposes and may be published. However, you will not be identified personally in such
publications. All research records will be stored in secure research offices. While we will do our best to
protect your information there is no guarantee that we will be able to do so.
Information gathered from the study will be made available to the investigators. Representatives of The
University of Western Ontario Health Sciences Research Ethics Board may require access to your study‐
related records or may contact you to monitor the conduct of the research. Representatives from Lawson
Health Research Institute may require access your study record for quality assurance purposes.
QUESTIONS / FURTHER INFORMATION
Please keep this Letter of Information and if you have any questions about this study, please do not hesitate
to contact your urologist or the study coordinator. If you no longer wish to participate in the study, you
must let your urologist or the study coordinator know.
Investigators/Urologists
519‐646‐6259
Dr. Razvi
Dr. Pautler
519‐646‐6384
Dr. Denstedt 519‐646‐6036
The study Coordinator can be reached at 519‐646‐6310
A copy of your signed consent form will be made available to you.
If you have any questions about your rights as a research participant or the conduct of the study you may
contact Dr. David Hill, Scientific Director, Lawson Health Research Institute at 519‐646‐4716.

Biomarkers of Kidney Injury in a Urological Population
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Biomarkers of Kidney Injury in a Urological Population

CONSENT FORM

I, __________________________________________________________________ have read
the Letter of Information, have had the nature of the study explained to me and I agree to
participate. All questions have been answered to my satisfaction.

__________________
Date

_____________________________
Signature of Participant

______________________________
Name of person responsible for
obtaining this consent

__________________
Date

_____________________________
Signature of person responsible for
obtaining this consent

Biomarkers of Kidney Injury in a Urological Population
Version dated 9 December2014
Page 3 of 3
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Appendix 4 – Inclusion and Exclusion Criteria Checklists
A) Patients

Biomarkers of Kidney Injury in a Urological Population

Patient Name:__________________________________________ JNumber:_____________________
Patients….
can only be enrolled once in this study;
must be planning on returning here for both follow-up appointments.
INCLUSION & EXCLUSION CRITERIA

= Yes, INCLUSION CRITERIA
Patients with ureteropelvic junction obstruction (UPJO) or
ureteral stricture causing unilateral hydronephrosis:
Patients at least 18 years old;
Patients willing to provide informed consent;
Patients with diagnosis of UPJO or ureteral stricture
associated with unilateral hydronephrosis;
Patients with UPJO may have a renal stone, but it should
not be the cause of the obstruction;
Patients with a diuretic renogram performed before the
surgical intervention/procedure.

= Yes, INCLUSION CRITERIA
Patients with stone disease without hydronephrosis:
Patients at least 18 years old;
Patients willing to provide informed consent;
Patients scheduled for PCNL or ureteroscopy to treat
kidney stone(s);
Patients with CT KUB scan or a KUB and a renal
ultrasound;
CT-KUB or renal ultrasound negative for
hydronephrosis;
Patients with at least one determination of serum
creatinine in the last 6 months.

= No, EXCLUSION CRITERIA
Patients with ureteropelvic junction obstruction (UPJO) or
ureteral stricture causing unilateral hydronephrosis:
Active urinary tract infection;
Patients with an indwelling ureteric stent;
Use of indwelling bladder catheter;
Recent history of sepsis or septic shock (< 3 months);
If it is in the treating urologist’s opinion that participation
in this study is not in the patient’s best interest.

= No, EXCLUSION CRITERIA
Patients with stone disease without hydronephrosis:
Presence of a ureteric stent;
Active urinary tract infection;
Patients with hydronephrosis defined by dilation of
renal pelvis or calyces seen on CT scan or renal
ultrasound at least 3 months before the surgical
procedure;
Use of indwelling bladder catheter;
Recent history of sepsis or septic shock (< 3 months);
If it is in the treating urologist’s opinion that
participation in this study is not in the patient’s best
interest.

= Yes, INCLUSION CRITERIA
Patients with unilateral hydronephrosis due to stone disease
without need for urgent management:
Patients at least 18 years old;
Patients with unilateral stone disease located in ureter or
at ureteropelvic junction:
Patients with a CT KUB or KUB and renal ultrasound
performed before the surgical intervention/procedure;
Presence of hydronephrosis on the affected side;
Patients with a serum creatinine measured no more than
6 months before the surgical intervention/procedure;
Patients scheduled for PCNL or ureteroscopy to relieve
the obstruction.
= No, EXCLUSION CRITERIA
Patients with unilateral hydronephrosis due to stone disease
without need for urgent management:
Contralateral hydronephrosis from any cause;
Active urinary tract infection;
Use of indwelling bladder catheter;
Recent history of sepsis or septic shock (< 3 months);
If it is in the treating urologist’s opinion that participation
in this study is not in the patient’s best interest.

Comments:
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B) Controls

Biomarkers of Kidney Injury in a Urological Population

Name:______________________________________________________________________________
Subjects can only be enrolled once in this study.

INCLUSION CRITERIA
= Yes
Healthy subjects (Control group):
At least 18 years of age;
Willing to provide informed consent;
Able to provide a voided urine simple;
Willing to have a renal ultrasound.

EXCLUSION CRITERIA
= No
Healthy subjects (Control group):
Previous personal or family history of stone disease by patient history;
Abnormal renal ultrasound;
Abnormal dip-stick urinalysis:
Blood, leukocytes, nitrites, proteins or glucose is positive.
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Appendix 5 – Coding of the analyzed variables
Appendix 5: Coding of analyzed variables
Baseline variables
Demographics
Age
BMI
Gender
Past medical hisotry
CCI
Diabetes
Hypertension
Previous stone disease
Clinical
Episode related to renal colic
Length of time from colic to enrollment
Planned procedure
Recent visit to ER
Radiological
Imaging study (CT scan/Renal US)
Presence and grade of hydronephrosis
Presence of stone/ureteric stricture
Grade of hydronephrosis (Modified
Fernbach & Ito classification)
Single or multiple stone disease
Location of the stone (kidney, UPJ,
ureter)
Largest diameter of stone
Additional incidental findings in imaging
Laboratory findings
Preoperative serum creatinine
eGFR according CKD-EPI formula
Presence of leukocyturia in urinalysis
Number of leukocytes in urine
Urinary creatinine
Absolute urinary levels of KIM-1,
monomeric & homodimeric NGAL
Normalized urinary levels of KIM-1,
monomeric & homodimeric NGAL

Type of Variable
Continuous
Continuous
Categorical, dichotomous

Values
0-99
15-50
Male, Female

Units
years
kg/m2

Categorical, ordinal
Categorical, dichotomous
Categorical, dichotomous
Categorical, dichotomous

0->8
Yes, No
Yes, No
Yes, No

Categorical, dichotomous
Continuous
Categorical, nominal
Categorical, dichotomous

Yes, No
1-99
URS, PCNL, Pyeloplasty
Yes, No

Categorical, nominal
Categorical, dichotomous
Categorical, dichotomous

CT Scan, Renal US
Yes, No
Yes, No

Categorical, ordinal

0-4

Categorical, dichotomous

Single, Multiple

Categorical, nominal

Kidney, UPJ, Ureter

Continuous
Qualitative

0-50

mm

Continuous
Continuous
Categorical, dichotomous
Continuous
Continuous

50-500
0-120
Yes, No
0->500
0-50

mg/mL
ml/min
cells/uL
mg/mL

Continuous

0-2000

ng/mL

Continuous

10-1000

ng/mg creatinine

weeks
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Follow-up
Clinical
Presence of ureteric stent
Radiological
Imaging study for follow up
Presence of residual stones
Number of residual stones
Presence and grade of hydronephrosis
Grade of hydronephrosis (Modified
Fernbach & Ito classification)
Biochemical
Presence of leukocyturia in urinalysis
Number of leukocytes in urine
Urinary creatinine
Absolute urinary levels of KIM-1,
monomeric & homodimeric NGAL
Normalized urinary levels of KIM-1,
monomeric & homodimeric NGAL
Presence of incidental findings on
imaging studies

Categorical, dichotomous

Yes, No

Categorical, nominal
Categorical, dichotomous
Categorical, dichotomous
Categorical, dichotomous

CT Scan, Renal US, KUB
Yes, No
Single, mutiple
Yes, No

Categorical, ordinal

0-4

Categorical, dichotomous
Continuous
Continuous

Yes, No
0->500
0-50

cells/uL
mg/mL

Continuous

0-2000

ng/mL

Continuous

0-100

ng/mg creatinine

Qualitative

* CCI: Charlson Comorbidity Index; ER: Emergency Room; HTN: hypertension; KUB: kidney-ureter-bladder x-rays;
UA: urinalysis; UPJ: ureteropelvic junction; US: ultrasound.
Units abbreviations: mg, miligram; mL, mililiter; ng, nanogram.
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